IEX 10-Q Quarterly Report Sept. 30, 2020 | Alphaminr
ALPHAMINR

IEX 10-Q Quarter ended Sept. 30, 2020

Balance Sheet
Cash Flow
Income Statement
Debt
IDEX CORP /DE/
10-Qs and 10-Ks
10-K
 		Fiscal year ended Dec. 31, 2024
10-Q
 		Quarter ended Sept. 30, 2024
10-Q
 		Quarter ended June 30, 2024
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
10-Q
 		Quarter ended Sept. 30, 2012
10-Q
 		Quarter ended June 30, 2012
10-Q
 		Quarter ended March 31, 2012
10-K
 		Fiscal year ended Dec. 31, 2011
10-Q
 		Quarter ended Sept. 30, 2011
10-Q
 		Quarter ended June 30, 2011
10-Q
 		Quarter ended March 31, 2011
10-K
 		Fiscal year ended Dec. 31, 2010
10-Q
 		Quarter ended Sept. 30, 2010
10-Q
 		Quarter ended June 30, 2010
10-Q
 		Quarter ended March 31, 2010
10-K
 		Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
 		Filed on March 26, 2025
DEF 14A
 		Filed on March 26, 2024
DEF 14A
 		Filed on April 4, 2023
DEF 14A
 		Filed on March 23, 2022
DEF 14A
 		Filed on March 23, 2021
DEF 14A
 		Filed on March 20, 2020
DEF 14A
 		Filed on March 22, 2019
DEF 14A
 		Filed on March 16, 2018
DEF 14A
 		Filed on March 17, 2017
DEF 14A
 		Filed on March 2, 2016
DEF 14A
 		Filed on March 2, 2015
DEF 14A
 		Filed on March 3, 2014
DEF 14A
 		Filed on Feb. 26, 2013
DEF 14A
 		Filed on March 7, 2012
DEF 14A
 		Filed on March 4, 2011
DEF 14A
 		Filed on March 5, 2010
iex-20200930
false 2020 Q3 0000832101 12/31 us-gaap:AccountingStandardsUpdate201602Member P5Y P1Y us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:AccruedLiabilitiesCurrent us-gaap:AccruedLiabilitiesCurrent P3Y 0000832101 2020-01-01 2020-09-30 xbrli:shares 0000832101 2020-10-23 iso4217:USD 0000832101 2020-09-30 0000832101 2019-12-31 iso4217:USD xbrli:shares 0000832101 2020-07-01 2020-09-30 0000832101 2019-07-01 2019-09-30 0000832101 2019-01-01 2019-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0000832101 us-gaap:RetainedEarningsMember 2019-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0000832101 us-gaap:TreasuryStockMember 2019-12-31 0000832101 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000832101 2020-01-01 2020-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-03-31 0000832101 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-03-31 0000832101 us-gaap:RetainedEarningsMember 2020-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-03-31 0000832101 us-gaap:TreasuryStockMember 2020-03-31 0000832101 2020-03-31 0000832101 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000832101 2020-04-01 2020-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-01 2020-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-04-01 2020-06-30 0000832101 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-06-30 0000832101 us-gaap:RetainedEarningsMember 2020-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000832101 us-gaap:TreasuryStockMember 2020-06-30 0000832101 2020-06-30 0000832101 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-07-01 2020-09-30 0000832101 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-09-30 0000832101 us-gaap:RetainedEarningsMember 2020-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-09-30 0000832101 us-gaap:TreasuryStockMember 2020-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0000832101 us-gaap:RetainedEarningsMember 2018-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000832101 us-gaap:TreasuryStockMember 2018-12-31 0000832101 2018-12-31 0000832101 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000832101 2019-01-01 2019-03-31 0000832101 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0000832101 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31 0000832101 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-03-31 0000832101 us-gaap:RetainedEarningsMember 2019-03-31 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000832101 us-gaap:TreasuryStockMember 2019-03-31 0000832101 2019-03-31 0000832101 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000832101 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-04-01 2019-06-30 0000832101 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-06-30 0000832101 us-gaap:RetainedEarningsMember 2019-06-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0000832101 us-gaap:TreasuryStockMember 2019-06-30 0000832101 2019-06-30 0000832101 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-07-01 2019-09-30 0000832101 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000832101 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-09-30 0000832101 us-gaap:RetainedEarningsMember 2019-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-09-30 0000832101 us-gaap:TreasuryStockMember 2019-09-30 0000832101 2019-09-30 xbrli:pure 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2020-09-30 0000832101 us-gaap:SeniorNotesMember iex:FourPointFivePercentageSeniorNotesMember 2020-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000832101 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000832101 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000832101 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000832101 iex:FlowManagementDevicesLLCMember 2020-02-28 2020-02-28 0000832101 iex:FlowManagementDevicesLLCMember 2020-02-28 0000832101 us-gaap:TradeNamesMember iex:FlowManagementDevicesLLCMember 2020-02-28 2020-02-28 0000832101 us-gaap:CustomerRelationshipsMember iex:FlowManagementDevicesLLCMember 2020-02-28 2020-02-28 0000832101 us-gaap:UnpatentedTechnologyMember iex:FlowManagementDevicesLLCMember 2020-02-28 2020-02-28 0000832101 iex:VelcoraHoldingABMember 2019-07-18 2019-07-18 0000832101 iex:VelcoraHoldingABMember 2019-07-18 0000832101 us-gaap:TradeNamesMember iex:VelcoraHoldingABMember 2019-07-18 2019-07-18 0000832101 us-gaap:CustomerRelationshipsMember iex:VelcoraHoldingABMember 2019-07-18 2019-07-18 0000832101 us-gaap:UnpatentedTechnologyMember iex:VelcoraHoldingABMember 2019-07-18 2019-07-18 0000832101 iex:VelcoraHoldingABMember 2019-07-01 2019-09-30 0000832101 srt:ScenarioForecastMember 2020-10-01 2020-12-31 0000832101 srt:ScenarioForecastMember 2020-12-31 iex:segment 0000832101 iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000832101 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000832101 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-12-31 0000832101 us-gaap:CorporateNonSegmentMember 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember 2019-12-31 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:EnergyMember 2019-01-01 2019-09-30 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:ValvesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:Water1Member 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:PumpsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:PumpsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:PumpsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:PumpsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:AgricultureMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:AgricultureMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:AgricultureMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:AgricultureMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:ScientificFluidicsandOpticsMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:SealingSolutionsMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:GastMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:MicropumpMember 2019-01-01 2019-09-30 0000832101 iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:MaterialProcessingTechnologiesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireandSafetyMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:BandItMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:DispensingMember 2019-01-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-07-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2020-07-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-07-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2020-01-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2020-01-01 2020-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 country:US us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 iex:NorthAmericaExcludingUnitedStatesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 srt:EuropeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember 2019-01-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 srt:AsiaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:OtherGeographicalAreasMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:OtherGeographicalAreasMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:OtherGeographicalAreasMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:OtherGeographicalAreasMember 2019-01-01 2019-09-30 0000832101 iex:BilledReceivablesMember 2020-09-30 0000832101 iex:BilledReceivablesMember 2019-12-31 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredAtPointInTimeMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredAtPointInTimeMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredAtPointInTimeMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000832101 us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredAtPointInTimeMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000832101 us-gaap:TransferredOverTimeMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000832101 iex:FluidAndMeteringTechnologiesMember 2019-12-31 0000832101 iex:HealthAndScienceTechnologiesMember 2019-12-31 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2019-12-31 0000832101 iex:FluidAndMeteringTechnologiesMember 2020-09-30 0000832101 iex:HealthAndScienceTechnologiesMember 2020-09-30 0000832101 iex:FireAndSafetyDiversifiedProductsMember 2020-09-30 0000832101 us-gaap:PatentsMember 2020-09-30 0000832101 us-gaap:PatentsMember 2020-01-01 2020-09-30 0000832101 us-gaap:PatentsMember 2019-12-31 0000832101 us-gaap:TradeNamesMember 2020-09-30 0000832101 us-gaap:TradeNamesMember 2020-01-01 2020-09-30 0000832101 us-gaap:TradeNamesMember 2019-12-31 0000832101 us-gaap:CustomerRelationshipsMember 2020-09-30 0000832101 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0000832101 us-gaap:CustomerRelationshipsMember 2019-12-31 0000832101 us-gaap:UnpatentedTechnologyMember 2020-09-30 0000832101 us-gaap:UnpatentedTechnologyMember 2020-01-01 2020-09-30 0000832101 us-gaap:UnpatentedTechnologyMember 2019-12-31 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2020-09-30 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2020-01-01 2020-09-30 0000832101 iex:OtherAmortizableIntangibleAssetsMember 2019-12-31 0000832101 iex:BanjoTradeNameMember 2020-09-30 0000832101 iex:BanjoTradeNameMember 2019-12-31 0000832101 iex:AkronBrasstradenameMember 2020-09-30 0000832101 iex:AkronBrasstradenameMember 2019-12-31 0000832101 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0000832101 us-gaap:UnpatentedTechnologyMember 2019-07-01 2019-09-30 0000832101 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0000832101 us-gaap:SeniorNotesMember iex:FourPointFivePercentageSeniorNotesMember 2019-12-31 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2020-09-30 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2020-09-30 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2020-09-30 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2019-12-31 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2020-04-29 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member 2020-04-29 2020-04-29 0000832101 us-gaap:SeniorNotesMember iex:FourPointFivePercentageSeniorNotesMember 2020-04-29 2020-04-29 0000832101 us-gaap:SeniorNotesMember iex:ThreePointZeroPercentSeniorNotesDueMay2030Member srt:MinimumMember 2020-04-29 0000832101 us-gaap:SeniorNotesMember iex:FourPointFivePercentageSeniorNotesMember 2020-05-27 2020-05-27 0000832101 us-gaap:RevolvingCreditFacilityMember 2015-06-23 2015-06-23 0000832101 us-gaap:RevolvingCreditFacilityMember 2015-06-23 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-05-31 0000832101 us-gaap:RevolvingCreditFacilityMember 2019-05-31 2019-05-31 0000832101 us-gaap:RevolvingCreditFacilityMember us-gaap:StandbyLettersOfCreditMember 2019-05-31 0000832101 us-gaap:RevolvingCreditFacilityMember iex:SwinglineLoansMember 2019-05-31 0000832101 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2020-09-30 0000832101 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2020-09-30 0000832101 iex:ThreePointTwoPercentSeniorNotesMember us-gaap:SeniorNotesMember 2016-06-13 0000832101 iex:ThreePointThreeSevenPercentSeniorNotesMember us-gaap:SeniorNotesMember 2016-06-13 0000832101 srt:MinimumMember 2016-06-13 0000832101 srt:MaximumMember us-gaap:SeniorNotesMember 2020-09-30 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2011-12-09 2011-12-09 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2011-12-09 iex:covenant 0000832101 srt:MinimumMember 2020-09-30 0000832101 srt:MaximumMember 2020-01-01 2020-09-30 0000832101 iex:For12MonthsinConnectionwithCertainAcquisitionsMember 2020-01-01 2020-09-30 iex:instrument 0000832101 us-gaap:InterestRateContractMember 2011-12-31 0000832101 iex:InterestRateExchangeAgreementExpiringTwoThousandTenandElevenMember 2010-01-01 2011-12-31 0000832101 iex:FourPointTwoPercentageSeniorNotesMember us-gaap:SeniorNotesMember 2020-01-01 2020-09-30 0000832101 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000832101 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000832101 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000832101 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000832101 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000832101 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000832101 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000832101 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000832101 iex:FingerLakesInstrumentationFLIMember 2018-07-23 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-09-30 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-09-30 0000832101 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000832101 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 iex:option 0000832101 us-gaap:BuildingMember 2020-09-30 0000832101 us-gaap:BuildingMember 2019-12-31 0000832101 us-gaap:EquipmentMember 2020-09-30 0000832101 us-gaap:EquipmentMember 2019-12-31 0000832101 iex:BuildingRightofUseAssetMember 2019-07-01 2019-09-30 0000832101 iex:BuildingAndEquipmentMember 2020-09-30 0000832101 iex:BuildingAndEquipmentMember 2019-12-31 0000832101 us-gaap:VehiclesMember 2020-09-30 0000832101 us-gaap:VehiclesMember 2019-12-31 0000832101 us-gaap:PropertyPlantAndEquipmentMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FluidAndMeteringTechnologiesMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AssetImpairmentChargeMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:FacilityClosingMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:AssetImpairmentChargeMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:AssetImpairmentChargeMember 2020-07-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2020-07-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember iex:AssetImpairmentChargeMember 2020-07-01 2020-09-30 0000832101 us-gaap:EmployeeSeveranceMember 2020-07-01 2020-09-30 0000832101 us-gaap:FacilityClosingMember 2020-07-01 2020-09-30 0000832101 iex:AssetImpairmentChargeMember 2020-07-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FluidAndMeteringTechnologiesMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AssetImpairmentChargeMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:FacilityClosingMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:AssetImpairmentChargeMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:AssetImpairmentChargeMember 2019-07-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2019-07-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember iex:AssetImpairmentChargeMember 2019-07-01 2019-09-30 0000832101 us-gaap:EmployeeSeveranceMember 2019-07-01 2019-09-30 0000832101 us-gaap:FacilityClosingMember 2019-07-01 2019-09-30 0000832101 iex:AssetImpairmentChargeMember 2019-07-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FluidAndMeteringTechnologiesMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AssetImpairmentChargeMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:AssetImpairmentChargeMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:AssetImpairmentChargeMember 2020-01-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0000832101 us-gaap:CorporateNonSegmentMember iex:AssetImpairmentChargeMember 2020-01-01 2020-09-30 0000832101 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000832101 us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0000832101 iex:AssetImpairmentChargeMember 2020-01-01 2020-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FluidAndMeteringTechnologiesMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FluidAndMeteringTechnologiesMember iex:AssetImpairmentChargeMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember us-gaap:FacilityClosingMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:HealthAndScienceTechnologiesMember iex:AssetImpairmentChargeMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember us-gaap:FacilityClosingMember iex:FireAndSafetyDiversifiedProductsMember 2019-01-01 2019-09-30 0000832101 us-gaap:OperatingSegmentsMember iex:FireAndSafetyDiversifiedProductsMember iex:AssetImpairmentChargeMember 2019-01-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember us-gaap:FacilityClosingMember 2019-01-01 2019-09-30 0000832101 us-gaap:CorporateNonSegmentMember iex:AssetImpairmentChargeMember 2019-01-01 2019-09-30 0000832101 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000832101 us-gaap:FacilityClosingMember 2019-01-01 2019-09-30 0000832101 iex:AssetImpairmentChargeMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-07-01 2020-09-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-07-01 2019-09-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2020-01-01 2020-09-30 0000832101 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000832101 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000832101 2020-03-17 2020-03-17 0000832101 2015-12-01 2015-12-01 0000832101 2014-11-06 0000832101 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000832101 us-gaap:EmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000832101 us-gaap:EmployeeStockOptionMember 2019-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000832101 us-gaap:EmployeeStockOptionMember 2020-09-30 0000832101 iex:EmployeesandNonemployeeDirectorsMember us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000832101 us-gaap:RestrictedStockMember 2019-12-31 0000832101 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000832101 us-gaap:RestrictedStockMember 2020-09-30 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000832101 us-gaap:CostOfSalesMember us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0000832101 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000832101 us-gaap:RestrictedStockMember 2020-07-01 2020-09-30 0000832101 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0000832101 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember 2020-01-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember 2019-12-31 0000832101 iex:CashsettledRestrictedStockMember 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember 2020-07-01 2020-09-30 0000832101 iex:CashsettledRestrictedStockMember 2019-07-01 2019-09-30 0000832101 iex:CashsettledRestrictedStockMember 2019-01-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember 2019-01-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember 2019-12-31 0000832101 us-gaap:PerformanceSharesMember 2020-09-30 0000832101 us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0000832101 us-gaap:PerformanceSharesMember 2020-02-01 2020-02-29 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000832101 us-gaap:PerformanceSharesMember 2020-07-01 2020-09-30 0000832101 us-gaap:PerformanceSharesMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2020-07-01 2020-09-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2019-07-01 2019-09-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2020-01-01 2020-09-30 0000832101 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2019-01-01 2019-09-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000832101 us-gaap:PensionPlansDefinedBenefitMember 2020-09-30 0000832101 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-09-30 iex:employee 0000832101 us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000832101 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000832101 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30
Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
Form 10-Q
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 1-10235
IDEX CORP ORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware 36-3555336
(State or other jurisdiction of
incorporation or organization) 		(I.R.S. Employer
Identification No.)
3100 Sanders Road, Suite 301, Northbrook, Illinois 60062
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number: ( 847 ) 498-7070

Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $.01 per share IEX New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Table of Contents

Large accelerated filer ☑
Accelerated filer ☐
Non-accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
Number of shares of common stock of IDEX Corporation outstanding as of October 23, 2020: 75,705,784 .

Table of Contents

TABLE OF CONTENTS
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 6.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

IDEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
September 30, 2020 December 31, 2019
ASSETS
Current assets
Cash and cash equivalents $ 877,758 $ 632,581
Receivables, less allowance for doubtful accounts of $ 6,089 at September 30, 2020 and $ 6,347 at December 31, 2019
275,432 298,186
Inventories 302,410 293,467
Other current assets 65,152 37,211
Total current assets 1,520,752 1,261,445
Property, plant and equipment - net 293,304 280,316
Goodwill 1,863,577 1,779,745
Intangible assets - net 417,080 388,031
Other noncurrent assets 130,882 104,375
Total assets $ 4,225,595 $ 3,813,912
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Trade accounts payable $ 134,782 $ 138,463
Accrued expenses 236,937 180,290
Short-term borrowings 150 388
Dividends payable 37,830 38,736
Total current liabilities 409,699 357,877
Long-term borrowings 1,044,112 848,864
Deferred income taxes 151,924 146,574
Other noncurrent liabilities 223,331 197,368
Total liabilities 1,829,066 1,550,683
Commitments and contingencies
Shareholders’ equity
Preferred stock:
Authorized: 5,000,000 shares, $ .01 per share par value; Issued: None
— —
Common stock:
Authorized: 150,000,000 shares, $ .01 per share par value
Issued: 89,919,727 shares at September 30, 2020 and 89,948,374 shares at December 31, 2019
899 899
Additional paid-in capital 778,469 760,453
Retained earnings 2,778,130 2,615,131
Treasury stock at cost: 14,260,042 shares at September 30, 2020 and 13,860,340 shares at December 31, 2019
( 1,079,720 ) ( 985,909 )
Accumulated other comprehensive income (loss) ( 81,249 ) ( 127,345 )
Total shareholders’ equity 2,396,529 2,263,229
Total liabilities and shareholders’ equity $ 4,225,595 $ 3,813,912
See Notes to Condensed Consolidated Financial Statements
1
Table of Contents

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Net sales $ 581,113 $ 624,246 $ 1,736,824 $ 1,888,576
Cost of sales 329,613 342,268 978,568 1,030,427
Gross profit 251,500 281,978 758,256 858,149
Selling, general and administrative expenses 117,370 128,257 369,750 399,237
Restructuring expenses 2,917 11,956 6,758 14,082
Operating income 131,213 141,765 381,748 444,830
Other (income) expense - net ( 704 ) 1,219 7,321 701
Interest expense 10,642 11,330 33,958 33,262
Income before income taxes 121,275 129,216 340,469 410,867
Provision for income taxes 17,427 24,022 63,759 82,196
Net income $ 103,848 $ 105,194 $ 276,710 $ 328,671
Basic earnings per common share $ 1.38 $ 1.39 $ 3.66 $ 4.34
Diluted earnings per common share $ 1.37 $ 1.37 $ 3.64 $ 4.30
Share data:
Basic weighted average common shares outstanding 75,352 75,698 75,423 75,532
Diluted weighted average common shares outstanding 75,960 76,577 76,119 76,415
See Notes to Condensed Consolidated Financial Statements
2
Table of Contents

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Net income $ 103,848 $ 105,194 $ 276,710 $ 328,671
Other comprehensive income (loss):
Reclassification adjustments for derivatives, net of tax
672 1,210 3,982 3,661
Pension and other postretirement adjustments, net of tax
291 1,663 1,956 4,181
Cumulative translation adjustment
47,343 ( 37,825 ) 40,158 ( 38,478 )
Other comprehensive income (loss)
48,306 ( 34,952 ) 46,096 ( 30,636 )
Comprehensive income $ 152,154 $ 70,242 $ 322,806 $ 298,035
See Notes to Condensed Consolidated Financial Statements
3
Table of Contents

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands except share amounts)
(unaudited)

Accumulated Other Comprehensive
Income (Loss)
Common
Stock and
Additional
Paid-In Capital 		Retained
Earnings 		Cumulative
Translation
Adjustment 		Retirement
Benefits
Adjustment 		Cumulative
Unrealized Gain (Loss) on
Derivatives 		Treasury
Stock 		Total
Shareholders’
Equity
Balance, December 31, 2019 $ 761,352 $ 2,615,131 $ ( 94,353 ) $ ( 25,809 ) $ ( 7,183 ) $ ( 985,909 ) $ 2,263,229
Net income — 101,998 — — — — 101,998
Cumulative translation adjustment — — ( 26,456 ) — — — ( 26,456 )
Net change in retirement obligations (net of tax of $ 578 )
— — — 2,296 — — 2,296
Net change on derivatives designated as cash flow hedges (net of tax of $ 351 )
— — — — 1,194 — 1,194
Issuance of 131,757 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 3,061 )
— — — — — 2,089 2,089
Repurchase of 866,823 shares of common stock
— — — — — ( 108,907 ) ( 108,907 )
Shares surrendered for tax withholding — — — — — ( 12,119 ) ( 12,119 )
Share-based compensation 6,463 — — — — — 6,463
Balance, March 31, 2020 $ 767,815 $ 2,717,129 $ ( 120,809 ) $ ( 23,513 ) $ ( 5,989 ) $ ( 1,104,846 ) $ 2,229,787
Net income — 70,864 — — — — 70,864
Cumulative translation adjustment — — 19,271 — — — 19,271
Net change in retirement obligations (net of tax of $ 62 )
— — — ( 631 ) — — ( 631 )
Net change on derivatives designated as cash flow hedges (net of tax of $ 623 )
— — — — 2,116 — 2,116
Issuance of 145,263 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 594 )
— — — — — 11,022 11,022
Repurchase of 9,600 shares of common stock
— — — — — ( 1,435 ) ( 1,435 )
Shares surrendered for tax withholding — — — — — ( 29 ) ( 29 )
Share-based compensation 5,753 — — — — — 5,753
Cash dividends declared - $ 1.00 per common share outstanding
— ( 75,681 ) — — — — ( 75,681 )
Balance, June 30, 2020 $ 773,568 $ 2,712,312 $ ( 101,538 ) $ ( 24,144 ) $ ( 3,873 ) $ ( 1,095,288 ) $ 2,261,037
Net income — 103,848 — — — — 103,848
Cumulative translation adjustment — — 47,343 — — — 47,343
Net change in retirement obligations (net of tax of $ 171 )
— — — 291 — — 291
Net change on derivatives designated as cash flow hedges (net of tax of $ 197 )
— — — — 672 — 672
Issuance of 191,432 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 837 )
— — — — — 15,618 15,618
Shares surrendered for tax withholding — — — — — ( 50 ) ( 50 )
Share-based compensation 5,800 — — — — — 5,800
Cash dividends declared - $ 0.50 per common share outstanding
— ( 38,030 ) — — — — ( 38,030 )
Balance, September 30, 2020 $ 779,368 $ 2,778,130 $ ( 54,195 ) $ ( 23,853 ) $ ( 3,201 ) $ ( 1,079,720 ) $ 2,396,529

See Notes to Condensed Consolidated Financial Statements


4
Table of Contents

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Continued)
(in thousands except share amounts)
(unaudited)

Accumulated Other Comprehensive
Income (Loss)
Common
Stock and
Additional
Paid-In Capital 		Retained
Earnings 		Cumulative
Translation
Adjustment 		Retirement
Benefits
Adjustment 		Cumulative
Unrealized Gain (Loss) on
Derivatives 		Treasury
Stock 		Total
Shareholders’
Equity
Balance, December 31, 2018 $ 739,240 $ 2,342,079 $ ( 94,420 ) $ ( 22,740 ) $ ( 12,065 ) $ ( 957,454 ) $ 1,994,640
Net income — 110,268 — — — — 110,268
Adjustment for adoption of ASU 2016-02
— 28 — — — — 28
Cumulative translation adjustment — — ( 3,281 ) — — — ( 3,281 )
Net change in retirement obligations (net of tax of $ 438 )
— — — 1,262 — — 1,262
Net change on derivatives designated as cash flow hedges (net of tax of $ 361 )
— — — — 1,227 — 1,227
Issuance of 264,090 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 3,415 )
— — — — — 8,870 8,870
Repurchase of 369,810 shares of common stock
— — — — — ( 51,706 ) ( 51,706 )
Shares surrendered for tax withholding — — — — — ( 11,479 ) ( 11,479 )
Share-based compensation 5,403 — — — — — 5,403
Balance, March 31, 2019 $ 744,643 $ 2,452,375 $ ( 97,701 ) $ ( 21,478 ) $ ( 10,838 ) $ ( 1,011,769 ) $ 2,055,232
Net income — 113,209 — — — — 113,209
Cumulative translation adjustment — — 2,628 — — — 2,628
Net change in retirement obligations (net of tax of $ 435 )
— — — 1,256 — — 1,256
Net change on derivatives designated as cash flow hedges (net of tax of $ 359 )
— — — — 1,224 — 1,224
Issuance of 169,785 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 679 )
— — — — — 11,891 11,891
Repurchase of 19,143 shares of common stock
— — — — — ( 2,962 ) ( 2,962 )
Shares surrendered for tax withholding — — — — — ( 30 ) ( 30 )
Share-based compensation 5,266 — — — — — 5,266
Cash dividends declared - $ 1.00 per common share outstanding
— ( 75,673 ) — — — — ( 75,673 )
Balance, June 30, 2019 $ 749,909 $ 2,489,911 $ ( 95,073 ) $ ( 20,222 ) $ ( 9,614 ) $ ( 1,002,870 ) $ 2,112,041
Net income — 105,194 — — — — 105,194
Cumulative translation adjustment — — ( 37,825 ) — — — ( 37,825 )
Net change in retirement obligations (net of tax of $ 525 )
— — — 1,663 — — 1,663
Net change on derivatives designated as cash flow hedges (net of tax of $ 356 )
— — — — 1,210 — 1,210
Issuance of 215,823 shares of common stock from issuance of unvested shares, performance share units and exercise of stock options (net of tax of $ 1,171 )
— — — — — 14,834 14,834
Shares surrendered for tax withholding — — — — — ( 1,074 ) ( 1,074 )
Share-based compensation 5,692 — — — — — 5,692
Cash dividends declared - $ 0.50 per common share outstanding
— ( 38,682 ) — — — — ( 38,682 )
Balance, September 30, 2019 $ 755,601 $ 2,556,423 $ ( 132,898 ) $ ( 18,559 ) $ ( 8,404 ) $ ( 989,110 ) $ 2,163,053

See Notes to Condensed Consolidated Financial Statements
5
Table of Contents

IDEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Nine Months Ended September 30,
2020 2019
Cash flows from operating activities
Net income $ 276,710 $ 328,671
Adjustments to reconcile net income to net cash provided by operating activities:
Asset impairments 85 9,680
Depreciation and amortization 30,851 29,599
Amortization of intangible assets 31,123 27,747
Amortization of debt issuance expenses 1,351 1,013
Share-based compensation expense 21,155 20,620
Deferred income taxes 1,323 11,528
Non-cash interest expense associated with forward starting swaps 5,153 4,737
Changes in (net of the effect from acquisitions):
Receivables 33,291 ( 2,071 )
Inventories 17,920 ( 16,987 )
Other current assets ( 27,655 ) ( 19,186 )
Trade accounts payable ( 11,496 ) 2,807
Accrued expenses 24,333 ( 23,222 )
Other - net 3,755 1,966
Net cash flows provided by operating activities 407,899 376,902
Cash flows from investing activities
Purchases of property, plant and equipment ( 39,438 ) ( 36,773 )
Acquisition of businesses, net of cash acquired ( 118,159 ) ( 87,180 )
Proceeds from disposal of fixed assets 2,230 957
Other - net ( 238 ) 407
Net cash flows used in investing activities ( 155,605 ) ( 122,589 )
Cash flows from financing activities
Borrowings under revolving credit facilities 150,000 —
Proceeds from issuance of 3.0 % Senior Notes
499,100 —
Payment of 4.5 % Senior Notes
( 300,000 ) —
Payments under revolving credit facilities ( 150,000 ) —
Payments under other long-term borrowings ( 352 ) ( 49,923 )
Payment of make-whole redemption premium ( 6,756 ) —
Debt issuance costs ( 4,741 ) —
Dividends paid ( 114,248 ) ( 109,227 )
Proceeds from stock option exercises 28,729 35,595
Repurchases of common stock ( 110,342 ) ( 54,668 )
Shares surrendered for tax withholding ( 12,198 ) ( 12,583 )
Other - net — ( 1,865 )
Net cash flows used in financing activities ( 20,808 ) ( 192,671 )
Effect of exchange rate changes on cash and cash equivalents 13,691 ( 12,064 )
Net increase in cash 245,177 49,578
Cash and cash equivalents at beginning of year 632,581 466,407
Cash and cash equivalents at end of period $ 877,758 $ 515,985
Supplemental cash flow information
Cash paid for:
Interest $ 16,415 $ 18,832
Income taxes 66,268 84,326
Significant non-cash activities:
Debt acquired with acquisition of business $ — $ 51,130

See Notes to Condensed Consolidated Financial Statements
6
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

1. Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX,” “we,” “our,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the entire year.

The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit losses (Topic 326): Measurement of Credit Losses on Financial Instruments and in November 2018 issued a subsequent amendment, ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2016-13 significantly changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the prior “incurred loss” approach with an “expected loss” model for instruments measured at amortized cost. ASU 2018-19 affects loans, debt securities, trade receivables, net investments in leases, off-balance sheet credit exposures, reinsurance receivables and any other financial assets not excluded from the scope of this amendment that represent the contractual right to receive cash. ASU 2016-13 and ASU 2018-19 should be applied on either a prospective transition or modified-retrospective approach depending on the subtopic. The Company adopted this standard on January 1, 2020 using the prospective transition approach. The adoption of this standard did not have a material impact on our condensed consolidated financial statements.

2. Acquisitions and Divestitures

All of the Company’s acquisitions of businesses have been accounted for under Accounting Standards Codification (“ASC”) 805, Business Combinations . Accordingly, the accounts of the acquired companies, after adjustments to reflect the fair values assigned to assets and liabilities, have been included in the Company’s condensed consolidated financial statements from their respective dates of acquisition. The results of operations of the acquired companies have been included in the Company’s condensed consolidated results since the date of each acquisition.

The Company incurred acquisition-related transaction costs of $ 1.3 million and $ 0.6 million in the three months ended September 30, 2020 and 2019, respectively, and $ 3.1 million and $ 1.3 million in the nine months ended September 30, 2020 and 2019, respectively. These costs were recorded in Selling, general and administrative expenses and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed. The Company also incurred a $ 4.1 million fair value inventory step-up charge associated with the completed 2020 acquisition of Flow Management Devices, LLC (“Flow MD”) described below in the nine months ended September 30, 2020 and a $ 3.3 million fair value inventory step-up charge associated with the completed 2019 acquisition of Velcora Holding AB (“Velcora”) described below in the three and nine months ended September 30, 2019. These charges were recorded in Cost of sales.

2020 Acquisition

On February 28, 2020, the Company acquired the stock of Flow MD, a privately held provider of flow measurement systems that ensure custody transfer accuracy in the oil and gas industry. Flow MD engineers and manufactures small volume provers. Headquartered in Phoenix, AZ, with operations in Houston, TX and Pittsburgh, PA, Flow MD operates in our Energy group within the Fluid & Metering Technologies segment. Flow MD was acquired for cash consideration of $ 118.2 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $ 61.7 million and $ 53.0 million, respectively. The goodwill is deductible for tax purposes.

7
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
The Company made an initial allocation of the purchase price for the Flow MD acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information about these assets and liabilities, including intangible asset appraisals, inventory valuation and accrued expenses, and continues to learn more about the newly acquired business, we will refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company will continue to make required adjustments to the purchase price allocation prior to the completion of the measurement period.

The preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
(In thousands) Total
Current assets, net of cash acquired $ 32,980
Property, plant and equipment 4,230
Goodwill 61,739
Intangible assets 53,000
Other noncurrent assets 1,344
Total assets acquired 153,293
Current liabilities ( 35,554 )
Deferred income taxes 749
Other noncurrent liabilities ( 329 )
Net assets acquired (1)
$ 118,159

(1) During the third quarter of 2020, the Company finalized the purchase price of the Flow MD business, resulting in a $ 2.7 million adjustment to the purchase price.

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of this business.

The acquired intangible assets and weighted average amortization periods are as follows:
(In thousands, except weighted average life) Total Weighted Average Life
Trade names $ 6,000 15
Customer relationships 31,500 10
Unpatented technology 15,500 20
Acquired intangible assets $ 53,000

2019 Acquisition

On July 18, 2019, the Company acquired the stock of Velcora and its operating subsidiaries, Roplan and Steridose. Roplan is a global manufacturer of custom mechanical and shaft seals for a variety of end markets including food and beverage, marine, chemical, wastewater and water treatment. Steridose develops engineered hygienic mixers and valves for the global biopharmaceutical industry. Both companies are headquartered in Sweden but also have operations in China, the United Kingdom and the United States. Roplan and Steridose operate in our Health & Science Technologies segment. Velcora was acquired for cash consideration of $ 87.2 million and the assumption of $ 51.1 million of debt. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $ 86.6 million and $ 48.2 million, respectively. The goodwill is not deductible for tax purposes.

The Company finalized the allocation of the purchase price for the Velcora acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy.
8
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:
(In thousands) Total
Current assets, net of cash acquired $ 20,248
Property, plant and equipment 1,656
Goodwill 86,613
Intangible assets 48,183
Other noncurrent assets 788
Total assets acquired 157,488
Current liabilities ( 7,630 )
Long-term borrowings ( 51,130 )
Deferred income taxes ( 11,094 )
Other noncurrent liabilities ( 454 )
Net assets acquired $ 87,180

Acquired intangible assets consist of trade names, customer relationships and unpatented technology. The goodwill recorded for the acquisition reflects the strategic fit, revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:
(In thousands, except weighted average life) Total Weighted Average Life
Trade names $ 7,089 15
Customer relationships 34,677 12
Unpatented technology 6,417 9
Acquired intangible assets $ 48,183

On September 3, 2019, the Company settled the debt assumed in the Velcora acquisition and incurred a loss on early retirement of $ 0.7 million which was recorded in Other (income) expense - net in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019.

3. Joint Venture

On May 12, 2020, a subsidiary of IDEX entered into a joint venture agreement with a third party to form a limited liability company (the “Joint Venture”) that will manufacture and sell high performance elastomer seals for the oil and gas industry to customers within the Kingdom of Saudi Arabia as well as export these high performance elastomer seals outside of the Kingdom of Saudi Arabia. The Joint Venture will be headquartered in Damman, Saudi Arabia and will operate in our Sealing Solutions platform within the Health & Science Technologies segment. IDEX will contribute $ 0.6 million and will own 55 % of the share capital while the third party partner will contribute $ 0.5 million and will own 45 % of the share capital. As of September 30, 2020, the Joint Venture had not yet been funded or begun its operations. Since we will control the entity, we expect to consolidate the Joint Venture and record a noncontrolling interest in our financial statements once funding occurs and operations begin, both of which are currently expected to occur during the fourth quarter of 2020.

4. Business Segments

IDEX has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products.

9
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
The Fluid & Metering Technologies (“FMT”) segment designs, produces and distributes positive displacement pumps, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries.

The Health & Science Technologies (“HST”) segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded sealing components, custom mechanical and shaft seals for a variety of end markets including food and beverage, marine, chemical, wastewater and water treatment, engineered hygienic mixers and valves for the global biopharmaceutical industry, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications.

The Fire & Safety/Diversified Products (“FSDP”) segment designs, produces and develops firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

Information on the Company’s business segments is presented below based on the nature of products and services offered. The Company evaluates performance based on several factors, of which sales, operating income and operating margin are the primary financial measures. Intersegment sales are accounted for at fair value as if the sales were to third parties.


10
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Net sales
Fluid & Metering Technologies
External customers $ 220,553 $ 240,758 $ 666,187 $ 729,205
Intersegment sales 194 103 533 367
Total segment sales 220,747 240,861 666,720 729,572
Health & Science Technologies
External customers 219,671 228,988 658,361 685,848
Intersegment sales 707 622 1,744 1,305
Total segment sales 220,378 229,610 660,105 687,153
Fire & Safety/Diversified Products
External customers 140,889 154,500 412,276 473,523
Intersegment sales 7 43 20 1,222
Total segment sales 140,896 154,543 412,296 474,745
Intersegment elimination ( 908 ) ( 768 ) ( 2,297 ) ( 2,894 )
Total net sales $ 581,113 $ 624,246 $ 1,736,824 $ 1,888,576
Operating income
Fluid & Metering Technologies $ 58,402 $ 77,481 $ 176,111 $ 223,493
Health & Science Technologies 49,912 40,170 150,562 151,087
Fire & Safety/Diversified Products 37,103 41,967 103,977 125,909
Corporate office ( 14,204 ) ( 17,853 ) ( 48,902 ) ( 55,659 )
Total operating income 131,213 141,765 381,748 444,830
Interest expense 10,642 11,330 33,958 33,262
Other (income) expense - net ( 704 ) 1,219 7,321 701
Income before income taxes $ 121,275 $ 129,216 $ 340,469 $ 410,867
September 30,
2020 		December 31,
2019
Assets
Fluid & Metering Technologies $ 1,327,303 $ 1,150,712
Health & Science Technologies 1,535,745 1,507,108
Fire & Safety/Diversified Products 838,747 825,398
Corporate office 523,800 330,694
Total assets $ 4,225,595 $ 3,813,912

11
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
5. Revenue

IDEX is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. The Company’s products include industrial pumps, provers, compressors, flow meters, injectors, valves and related controls for use in a wide variety of process applications; precision fluidics solutions, including pumps, valves, degassing equipment, corrective tubing, fittings and complex manifolds, optical filters and specialty medical equipment and devices for use in life science applications; precision-engineered equipment for dispensing, metering and mixing paints; and engineered products for industrial and commercial markets, including fire and rescue, transportation equipment, oil and gas, electronics and communications.

Revenue is recognized when control of products or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those products or providing those services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. We determine the appropriate revenue recognition for our contracts with customers by analyzing the type, terms and conditions of each contract or arrangement with a customer.

Disaggregation of Revenue

We have a comprehensive offering of products, including technologies, built to customers’ specifications that are sold in niche markets throughout the world. We disaggregate our revenue from contracts with customers by reporting unit and geographical region for each of our segments as we believe it best depicts how the amount, nature, timing and uncertainty of our revenue and cash flows are affected by economic factors. Revenue was attributed to geographical region based on the location of the customer. The following tables present our revenue disaggregated by reporting unit and geographical region.

Revenue by reporting unit for the three and nine months ended September 30, 2020 and 2019 was as follows:

Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Energy $ 56,155 $ 42,876 $ 150,483 $ 122,882
Valves 26,901 30,764 78,822 89,955
Water 59,822 62,611 172,888 188,891
Pumps 59,585 84,936 201,970 260,321
Agriculture 18,284 19,674 62,557 67,523
Intersegment elimination ( 194 ) ( 103 ) ( 533 ) ( 367 )
Fluid & Metering Technologies 220,553 240,758 666,187 729,205
Scientific Fluidics & Optics 100,569 108,869 313,275 325,731
Sealing Solutions 50,726 51,389 151,257 148,326
Gast 32,173 32,699 87,558 104,007
Micropump 7,273 8,273 22,260 25,299
Material Processing Technologies 29,637 28,380 85,755 83,790
Intersegment elimination ( 707 ) ( 622 ) ( 1,744 ) ( 1,305 )
Health & Science Technologies 219,671 228,988 658,361 685,848
Fire & Safety 94,065 100,389 280,428 303,094
BAND-IT 22,692 26,087 64,228 81,757
Dispensing 24,139 28,067 67,640 89,894
Intersegment elimination ( 7 ) ( 43 ) ( 20 ) ( 1,222 )
Fire & Safety/Diversified Products 140,889 154,500 412,276 473,523
Total net sales $ 581,113 $ 624,246 $ 1,736,824 $ 1,888,576
12
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Revenue by geographical region for the three and nine months ended September 30, 2020 and 2019 was as follows:
Three Months Ended September 30, 2020
FMT HST FSDP IDEX
U.S. $ 122,352 $ 98,943 $ 65,369 $ 286,664
North America, excluding U.S. 13,706 5,417 5,680 24,803
Europe 43,855 59,509 37,437 140,801
Asia 26,010 52,197 25,378 103,585
Other (1)
14,824 4,312 7,032 26,168
Intersegment elimination ( 194 ) ( 707 ) ( 7 ) ( 908 )
Total net sales $ 220,553 $ 219,671 $ 140,889 $ 581,113
Three Months Ended September 30, 2019
FMT HST FSDP IDEX
U.S. $ 133,710 $ 103,891 $ 74,306 $ 311,907
North America, excluding U.S. 13,652 5,450 6,726 25,828
Europe 46,830 65,339 38,078 150,247
Asia 30,182 51,378 26,317 107,877
Other (1)
16,487 3,552 9,116 29,155
Intersegment elimination ( 103 ) ( 622 ) ( 43 ) ( 768 )
Total net sales $ 240,758 $ 228,988 $ 154,500 $ 624,246
Nine Months Ended September 30, 2020
FMT HST FSDP IDEX
U.S. $ 384,429 $ 288,042 $ 203,940 $ 876,411
North America, excluding U.S. 38,741 15,911 16,980 71,632
Europe 127,906 182,596 108,683 419,185
Asia 77,144 161,342 63,500 301,986
Other (1)
38,500 12,214 19,193 69,907
Intersegment elimination ( 533 ) ( 1,744 ) ( 20 ) ( 2,297 )
Total net sales $ 666,187 $ 658,361 $ 412,276 $ 1,736,824
Nine Months Ended September 30, 2019
FMT HST FSDP IDEX
U.S. $ 411,645 $ 309,135 $ 227,881 $ 948,661
North America, excluding U.S. 41,337 15,839 19,124 76,300
Europe 134,403 200,509 124,953 459,865
Asia 94,452 149,939 76,621 321,012
Other (1)
47,735 11,731 26,166 85,632
Intersegment elimination ( 367 ) ( 1,305 ) ( 1,222 ) ( 2,894 )
Total net sales $ 729,205 $ 685,848 $ 473,523 $ 1,888,576

(1) Other includes: South America, Middle East, Australia and Africa.

13
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
Contract Balances

The timing of revenue recognition, billings and cash collections can result in customer receivables, advance payments or billings in excess of revenue recognized. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables on our Condensed Consolidated Balance Sheets. Amounts are billed in accordance with contractual terms or as work progresses. Unbilled amounts arise when the timing of billing differs from the timing of revenue recognized, such as when contract provisions require specific milestones to be met before a customer can be billed. Unbilled amounts primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and the revenue recognized exceeds the amount billed to the customer as there is not yet a right to invoice in accordance with contractual terms. Unbilled amounts are recorded as a contract asset when the revenue associated with the contract is recognized prior to billing and derecognized when billed in accordance with the terms of the contract. Customer receivables are recorded at face amount less an allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts for expected losses as a result of customers’ inability to make required payments. Management evaluates the aging of customer receivable balances, the financial condition of its customers, historical trends and the time outstanding of specific balances to estimate the amount of customer receivables that may not be collected in the future and records the appropriate provision.

The composition of Customer receivables was as follows:
September 30, 2020 December 31, 2019
Billed receivables $ 266,074 $ 286,196
Unbilled receivables 10,385 11,922
Total customer receivables $ 276,459 $ 298,118

Advance payments, deposits and billings in excess of revenue recognized are included in Deferred revenue which is classified as current or noncurrent based on the timing of when we expect to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on our Condensed Consolidated Balance Sheets. Advance payments or deposits represent contract liabilities and are recorded when customers remit contractual cash payments in advance of us satisfying performance obligations under contractual arrangements, including those with performance obligations satisfied over time. We generally receive advance payments from customers related to maintenance services which we recognize ratably over the service term. We also receive deposits from customers on certain orders which we recognize as revenue at a point in time. Billings in excess of revenue recognized represent contract liabilities and primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and revenue cannot yet be recognized as the Company has not completed the corresponding performance obligation. Contract liabilities are derecognized when revenue is recognized and the performance obligation is satisfied.

The composition of Deferred revenue was as follows:
September 30, 2020 December 31, 2019
Deferred revenue - current $ 41,840 $ 17,633
Deferred revenue - noncurrent 5,100 2,129
Total deferred revenue $ 46,940 $ 19,762

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct product or service to the customer. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For our contracts that require complex design, manufacturing and installation activities, certain performance obligations may not be separately identifiable from other performance obligations in the contract and, therefore, not distinct. As a result, the entire contract is accounted for as a single performance obligation. For our contracts that include distinct products or services that are substantially the same and have the same pattern of transfer to the customer over time, they are recognized as a series of distinct products or services. Certain of our contracts have multiple performance obligations for which we allocate the transaction price to each performance obligation using an estimate of the standalone selling price of each distinct product or service in the contract. For product sales, each product sold to a customer generally represents a distinct performance
14
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
obligation. In such cases, the observable standalone sales are used to determine the standalone selling price. In certain cases, we may be required to estimate standalone selling price using the expected cost plus margin approach, under which we forecast our expected costs of satisfying a performance obligation and then add an appropriate margin for that distinct product or service.

Our performance obligations are satisfied at a point in time or over time as work progresses. Performance obligations are supported by contracts with customers that provide a framework for the nature of the distinct product or service or bundle of products and services. We define service revenue as revenue from activities that are not associated with the design, development or manufacture of a product or the delivery of a software license.

Revenue from products and services transferred to customers at a point in time approximated 95 % of total revenues in both the three and nine months ended September 30, 2020 and 2019. Revenue on these contracts is recognized when obligations under the terms of the contract with our customer are satisfied. Generally, this occurs with the transfer of control of the asset, which is in line with shipping terms.

Revenue from products and services transferred to customers over time approximate d 5 % of total revenues in both the three and nine months ended September 30, 2020 and 2019. Revenue earned by certain business units within the Water, Energy, Material Processing Technologies (“MPT”) and Dispensing reporting units is recognized over time because control transfers continuously to our customers. When accounting for over-time contracts, we use an input measure to determine the extent of progress towards completion of the performance obligation. For certain business units within the Water, Energy and MPT reporting units, revenue is recognized over time as work is performed based on the relationship between actual costs incurred to date for each contract and the total estimated costs for such contract at completion of the performance obligation (i.e. the cost-to-cost method). We believe this measure of progress best depicts the transfer of control to the customer which occurs as we incur costs on our contracts. Incurred cost represents work performed, which corresponds with the transfer of control to the customer. Contract costs include labor, material and overhead. Contract estimates are based on various assumptions to project the outcome of future events. These assumptions include labor productivity and availability; the complexity of the work to be performed; the cost and availability of materials; the performance of subcontractors; and the availability and timing of funding from the customer. Revenues, including estimated fees or profits, are recorded proportionally as costs are incurred. For certain business units within the Energy and Dispensing reporting units, revenue is recognized ratably over the contract term.

As a significant change in one or more of these estimates could affect the profitability of our contracts, we review and update our estimates regularly. Due to uncertainties inherent in the estimation process, it is reasonably possible that completion costs, including those arising from contract penalty provisions and final contract settlements, will be revised. Such revisions to costs and income are recognized in the period in which the revisions are determined as a cumulative catch-up adjustment. The impact of the adjustment on profit recorded to date on a contract is recognized in the period the adjustment is identified. Revenue and profit in future periods of contract performance are recognized using the adjusted estimate. If at any time the estimate of contract profitability indicates an anticipated loss on the contract, we recognize provisions for estimated losses on incomplete contracts in the period in which such losses are determined.

The Company records allowances for discounts and product returns at the time of sale as a reduction of revenue as such allowances can be reliably estimated based on historical experience and known trends. The Company also offers product warranties (primarily assurance-type) and accrues its estimated exposure for warranty claims at the time of sale based upon the length of the warranty period, warranty costs incurred and any other related information known to the Company.

6. Earnings Per Common Share

Earnings per common share (“EPS”) is computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, restricted stock and performance share units.

ASC 260, Earnings Per Share, concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding shares of restricted stock are participating securities. Accordingly, EPS was computed using the two-class method prescribed by ASC 260.
15
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Basic weighted average common shares outstanding 75,352 75,698 75,423 75,532
Dilutive effect of stock options, restricted stock and performance share units 608 879 696 883
Diluted weighted average common shares outstanding 75,960 76,577 76,119 76,415

Options to purchase approximately 0.3 million shares of common stock for each of the three months ended September 30, 2020 and 2019, and 0.6 million shares of common stock for each of the nine months ended September 30, 2020 and 2019, respectively, were not included in the computation of diluted EPS because the effect of their inclusion would have been antidilutive.

7. Inventories

The components of inventories as of September 30, 2020 and December 31, 2019 were:
September 30,
2020 		December 31,
2019
Raw materials and component parts $ 187,244 $ 182,382
Work in process 30,093 28,761
Finished goods 85,073 82,324
Total inventories $ 302,410 $ 293,467

Inventories are stated at the lower of cost or net realizable value. Cost, which includes material, labor and factory overhead, is determined on a first in, first out basis.

8. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the nine months ended September 30, 2020, by reportable business segment, were as follows:
FMT HST FSDP IDEX
Goodwill $ 599,646 $ 981,592 $ 399,138 $ 1,980,376
Accumulated goodwill impairment losses ( 20,721 ) ( 149,820 ) ( 30,090 ) ( 200,631 )
Balance at December 31, 2019 578,925 831,772 369,048 1,779,745
Foreign currency translation 4,726 9,832 5,737 20,295
Acquisitions 61,739 — — 61,739
Acquisition adjustments — 1,798 — 1,798
Balance at September 30, 2020 $ 645,390 $ 843,402 $ 374,785 $ 1,863,577

ASC 350, Goodwill and Other Intangible Assets, requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. In the first nine months of 2020, there were no events or circumstances that would have required an interim impairment test. Annually, on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. Based on the results of our annual impairment test at October 31, 2019, all reporting units had fair values in excess of their carrying values.

16
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at September 30, 2020 and December 31, 2019:
At September 30, 2020 At December 31, 2019
Gross
Carrying
Amount 		Accumulated
Amortization 		Net Weighted
Average
Life 		Gross
Carrying
Amount 		Accumulated
Amortization 		Net
Amortized intangible assets:
Patents $ 2,865 $ ( 1,668 ) $ 1,197 10 $ 6,678 $ ( 5,276 ) $ 1,402
Trade names 128,393 ( 69,568 ) 58,825 16 123,062 ( 64,938 ) 58,124
Customer relationships 313,977 ( 115,815 ) 198,162 13 275,575 ( 96,252 ) 179,323
Unpatented technology 119,233 ( 51,307 ) 67,926 13 101,721 ( 43,561 ) 58,160
Other 700 ( 630 ) 70 10 700 ( 578 ) 122
Total amortized intangible assets 565,168 ( 238,988 ) 326,180 507,736 ( 210,605 ) 297,131
Indefinite-lived intangible assets:
Banjo trade name 62,100 — 62,100 62,100 — 62,100
Akron Brass trade name 28,800 — 28,800 28,800 — 28,800
Total intangible assets $ 656,068 $ ( 238,988 ) $ 417,080 $ 598,636 $ ( 210,605 ) $ 388,031

The Banjo trade name and the Akron Brass trade name are indefinite-lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. In the first nine months of 2020, there were no events or circumstances that would have required an interim impairment test on these indefinite-lived intangible assets. The Company uses the relief-from-royalty method, a form of the income approach, to determine the fair value of these trade names. The relief-from-royalty method is dependent on a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates.

In the first nine months of 2020, the outbreak of the novel coronavirus (“COVID-19”) resulted in government lockdown mandates globally that forced us to both reduce hours and temporarily close some facilities. These events required that an interim impairment test be performed on the definite-lived intangible assets at one of the Company’s businesses. The impairment test did no t result in an impairment charge.

In the second quarter of 2019, the Company began to evaluate strategic alternatives for one of its businesses in the HST segment. Prior to making a final decision on the options that were presented for this business, the business was informed in the third quarter of 2019 of the loss of its largest customer. As a result, the Company accelerated its restructuring activities for this business and a decision was made to wind down the business over time. This event required an interim impairment test be performed on certain of its definite-lived intangible assets, which resulted in an impairment charge of $ 7.1 million, consisting of $ 6.1 million related to customer relationships and $ 1.0 million related to unpatented technology. This charge was recorded as Restructuring expense in the three and nine months ended September 30, 2019. See Note 15 for further discussion.

Amortization of intangible assets was $ 11.1 million and $ 31.1 million for the three and nine months ended September 30, 2020, respectively. Amortization of intangible assets was $ 9.7 million and $ 27.7 million for the three and nine months ended September 30, 2019, respectively. Based on the intangible asset balances as of September 30, 2020, amortization expense is expected to approximate $ 10.8 million for the remaining three months of 2020, $ 42.2 million in 2021, $ 40.3 million in 2022, $ 37.6 million in 2023 and $ 35.8 million in 2024.

17
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
9. Accrued Expenses

The components of accrued expenses as of September 30, 2020 and December 31, 2019 were:
September 30,
2020 		December 31,
2019
Payroll and related items $ 75,658 $ 77,556
Management incentive compensation 10,945 14,408
Income taxes payable 31,279 9,905
Insurance 11,955 8,240
Warranty 7,082 5,581
Deferred revenue 41,840 17,633
Lease liability 15,896 15,235
Restructuring 4,026 6,110
Liability for uncertain tax positions — 890
Accrued interest 12,774 1,735
Contingent consideration for acquisition — 3,375
Other 25,482 19,622
Total accrued expenses $ 236,937 $ 180,290

10. Other Noncurrent Liabilities

The components of other noncurrent liabilities as of September 30, 2020 and December 31, 2019 were:
September 30,
2020 		December 31,
2019
Pension and retiree medical obligations $ 86,325 $ 87,478
Transition tax payable 14,208 11,292
Liability for uncertain tax positions 1,071 3,008
Deferred revenue 5,100 2,129
Lease liability 93,507 69,928
Other 23,120 23,533
Total other noncurrent liabilities $ 223,331 $ 197,368

18
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
11. Borrowings

Borrowings at September 30, 2020 and December 31, 2019 consisted of the following:
September 30,
2020 		December 31,
2019
Revolving Facility $ — $ —
4.50 % Senior Notes, due December 2020
— 300,000
4.20 % Senior Notes, due December 2021
350,000 350,000
3.20 % Senior Notes, due June 2023
100,000 100,000
3.37 % Senior Notes, due June 2025
100,000 100,000
3.00 % Senior Notes, due May 2030
500,000 —
Other borrowings 275 622
Total borrowings 1,050,275 850,622
Less current portion 150 388
Less deferred debt issuance costs 5,019 983
Less unaccreted debt discount 994 387
Total long-term borrowings $ 1,044,112 $ 848,864

On April 29, 2020, the Company completed a public offering of $ 500.0 million in aggregate principal amount of 3.0 % Senior Notes due 2030 (the “ 3.0 % Senior Notes”). The net proceeds from the offering were approximately $ 494.4 million, after deducting the issuance discount of $ 0.9 million, the underwriting commission of $ 3.3 million and offering expenses of $ 1.4 million. The net proceeds were used to redeem and repay the $ 300.0 million aggregate principal amount outstanding of its 4.5 % Senior Notes due December 15, 2020 and the related accrued interest and a make-whole redemption premium, with the balance used for general corporate purposes. The 3.0 % Senior Notes bear interest at a rate of 3.0 % per annum, which is payable semi-annually in arrears on May 1 and November 1 of each year. The 3.0 % Senior Notes mature on May 1, 2030.

The Company may redeem all or a portion of the 3.0 % Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture (“Indenture”) governing the 3.0 % Senior Notes. The Indenture and 3.0 % Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all of the Company’s assets. The terms of the 3.0 % Senior Notes also require the Company to make an offer to repurchase the 3.0 % Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101 % of the principal amount plus accrued and unpaid interest, if any. The Indenture also provides for customary events of default, which include nonpayment, breach of covenants in the Indenture and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25 % of the then outstanding 3.0 % Senior Notes may declare the principal amount of all of the 3.0 % Senior Notes to be due and payable immediately.

On April 27, 2020, the Company provided notice of its election to redeem early, on May 27, 2020, the $ 300.0 million aggregate principal amount outstanding of its 4.5 % Senior Notes at a redemption price of $ 300.0 million plus a make-whole redemption premium of $ 6.8 million and accrued and unpaid interest of $ 6.1 million using proceeds from the Company’s 3.0 % Senior Notes. In addition, the Company recognized the remaining $ 1.4 million of the pre-tax amount included in Accumulated other comprehensive income (loss) in shareholders’ equity related to the interest rate exchange agreement associated with the 4.5 % Senior Notes and wrote off the remaining $ 0.1 million of deferred issuance costs and $ 0.1 million of the debt issuance discount associated with the 4.5 % Senior Notes for a total loss on early debt redemption of $ 8.4 million which was recorded within Other (income) expense - net in the Condensed Consolidated Statements of Operations.

On May 31, 2019, the Company entered into a credit agreement (the “Credit Agreement”) along with certain of its subsidiaries, as borrowers (the “Borrowers”), Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, with other agents party thereto. The Credit Agreement replaced the Company’s prior five -year, $ 700 million credit agreement, dated as of June 23, 2015, which was due to expire in June 2020.

Terms and fees of the Credit Agreement are essentially the same as the prior credit agreement except for certain fees and interest rate pricing that are more favorable to the Company.
19
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

The Credit Agreement consists of a revolving credit facility (the “Revolving Facility”) in an aggregate principal amount of $ 800 million with a final maturity date of May 31, 2024. The maturity date may be extended under certain conditions for an additional one -year term. Up to $ 75 million of the Revolving Facility is available for the issuance of letters of credit. Additionally, up to $ 50 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.

Proceeds from the Revolving Facility are available for use by the Borrowers for acquisitions, working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments pursuant to such increases may not exceed $ 400 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement.

Borrowings under the Credit Agreement bear interest, at either an alternate base rate or adjusted LIBOR plus, in each case, an applicable margin. Such applicable margin is based on the lower of the Company’s senior, unsecured, long-term debt rating or the Company’s applicable leverage ratio and can range from 0.00 % to 1.275 %. Based on the Company’s leverage ratio at September 30, 2020, the applicable margin was 1.00 % resulting in a weighted average interest rate of 1.23 % for the nine months ended September 30, 2020. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR loans, on the last day of the applicable interest period selected, or every three months from the effective date of such interest period for interest periods exceeding three months.

The Credit Agreement requires payment to the lenders of a facility fee based upon the amount of the lenders’ commitments under the credit facility from time to time, determined based on the lower of the Company’s senior, unsecured long-term debt rating or the Company’s applicable leverage ratio. Voluntary prepayments of any loans and voluntary reductions of the unutilized portion of the commitments under the Credit Agreement are permissible without penalty, subject to break funding payments and minimum notice and minimum reduction amount requirements.

The Credit Agreement contains customary affirmative and negative covenants for senior unsecured credit agreements, including an interest coverage ratio test and a leverage ratio test, in each case tested quarterly and, in the case of the leverage ratio, with an option to increase the ratio for 12 months in connection with certain acquisitions. The negative covenants include restrictions on the Company’s ability to grant liens, enter into transactions resulting in fundamental changes (such as mergers or sales of all or substantially all of the assets of the Company), make certain subsidiary dividends or distributions, engage in materially different lines of businesses and allow subsidiaries to incur certain additional debt.

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate).

At September 30, 2020, there was no balance outstanding under the Revolving Facility and $ 7.0 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility at September 30, 2020 of approximately $ 793.0 million.

On June 13, 2016, the Company completed a private placement of a $ 100 million aggregate principal amount of 3.20 % Senior Notes due June 13, 2023 and a $ 100 million aggregate principal amount of 3.37 % Senior Notes due June 13, 2025 (collectively, the “Notes”) pursuant to a Note Purchase Agreement dated June 13, 2016 (the “Purchase Agreement”). Each series of Notes bears interest at the stated amount per annum, which is payable semi-annually in arrears on each June 13 th and December 13 th . The Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company may at any time prepay all, or any portion of the Notes, provided that such portion is greater than 5 % of the aggregate principal amount of the Notes then outstanding. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. In addition, the Company may repurchase the Notes by making an offer to all holders of the Notes, subject to certain conditions.

The Purchase Agreement contains certain covenants that restrict the Company’s ability to, among other things, transfer or sell assets, incur indebtedness, create liens, transact with affiliates and engage in certain mergers or consolidations or other change of control transactions. In addition, the Company must comply with a leverage ratio and interest coverage ratio, as
20
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
further described below, and the Purchase Agreement also limits the outstanding principal amount of priority debt that may be incurred by the Company to 15 % of consolidated assets. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all of the outstanding Notes will become due and payable immediately without further action or notice. In the case of a payment event of default, any holder of the Notes affected thereby may declare all of the Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the Notes may declare all of the Notes to be due and payable immediately.

On December 9, 2011, the Company completed a public offering of $ 350.0 million 4.2 % senior notes due December 15, 2021 (“ 4.2 % Senior Notes”). The net proceeds from the offering of $ 346.2 million, after deducting a $ 0.9 million issuance discount, a $ 2.3 million underwriting commission and $ 0.6 million of offering expenses, were used to repay $ 306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2 % Senior Notes bear interest at a rate of 4.2 % per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.2 % Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2 % Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2 % Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all of the Company’s assets. The terms of the 4.2 % Senior Notes also require the Company to make an offer to repurchase the 4.2 % Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101 % of their principal amount plus accrued and unpaid interest, if any.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the Notes: a minimum interest coverage ratio of 3.00 to 1 and a maximum leverage ratio of 3.50 to 1, which is the ratio of the Company’s consolidated total debt to its consolidated earnings before interest, income taxes, depreciation and amortization (“EBITDA”). In the case of the leverage ratio under the Revolving Facility, there is an option to increase the ratio to 4.00 for 12 months in connection with certain acquisitions. At September 30, 2020, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 3.0 % Senior Notes or 4.2 % Senior Notes; however, both are subject to cross-default provisions.

12. Derivative Instruments

The Company enters into cash flow hedges from time to time to reduce the exposure to variability in certain expected future cash flows. The types of cash flow hedges the Company enters into include foreign currency exchange contracts designed to minimize the earnings impact on certain intercompany loans as well as interest rate exchange agreements designed to reduce the impact of interest rate changes on future interest expense that effectively convert a portion of floating-rate debt to fixed-rate debt.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized in net income during the period of change. See Note 16 for the amount of loss reclassified into net income for interest rate contracts for the three and nine months ended September 30, 2020 and 2019. As of September 30, 2020, the Company did not have any interest rate contracts outstanding.

In 2010 and 2011, the Company entered into two separate forward starting interest rate exchange agreements in anticipation of the issuance of the 4.2 % Senior Notes and the 4.5 % Senior Notes. The Company cash settled these two interest rate contracts in 2010 and 2011 for a total of $ 68.9 million, which is being amortized into interest expense over the 10 year terms of the respective debt instruments. Approximately $ 3.4 million of the pre-tax amount included in Accumulated other comprehensive income (loss) in shareholders’ equity at September 30, 2020 related to the 4.2 % Senior Notes will be recognized in net income over the next 12 months as the underlying hedged transaction is realized. In conjunction with the early redemption of the 4.5 % Senior Notes on May 27, 2020, the Company accelerated the recognition of the remaining $ 1.4 million of the pre-tax amount included in Accumulated other comprehensive income (loss) in shareholders’ equity related to the 4.5 % Senior Notes and recorded such as Other (income) expense - net during the nine months ended September 30, 2020 in the Condensed Consolidated Statements of Operations.


21
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

13. Fair Value Measurements

ASC 820, Fair Value Measurements and Disclosures, defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

• Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
• Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
• Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheets at September 30, 2020 and December 31, 2019:
Basis of Fair Value Measurements
Balance at September 30, 2020 Level 1 Level 2 Level 3
Available for sale securities $ 12,136 $ 12,136 $ — $ —
Basis of Fair Value Measurements
Balance at December 31, 2019 Level 1 Level 2 Level 3
Available for sale securities $ 10,462 $ 10,462 $ — $ —
Contingent consideration 3,375 — — 3,375

There were no transfers of assets or liabilities between Level 1 and Level 2 during the three and nine months ended September 30, 2020 or the year ended December 31, 2019.

As of December 31, 2019, the Company utilized a Monte Carlo simulation to determine the fair value of the contingent consideration associated with the acquisition of Finger Lakes Instrumentation as of the acquisition date. In March 2020, the Company and the seller reached an agreement to settle the contingency for $ 3.0 million, which was paid in April 2020.
The carrying values of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair values because of the short term nature of these instruments. At September 30, 2020, the fair value of the outstanding indebtedness under our 3.0 % Senior Notes, 3.2 % Senior Notes, 3.37 % Senior Notes, 4.2 % Senior Notes and other borrowings based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $ 1,136.3 million compared to the carrying value of $ 1,049.3 million. At December 31, 2019, the fair value of the outstanding indebtedness under our 3.2 % Senior Notes, 3.37 % Senior Notes, 4.5 % Senior Notes, 4.2 % Senior Notes and other borrowings based on quoted market prices and current market rates for debt with similar credit risk and maturity was approximately $ 876.0 million compared to the carrying value of $ 850.2 million. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.

22
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
14. Leases

The Company leases certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles under operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term.

Certain leases include one or more options to renew. The exercise of lease renewal options is at the Company’s sole discretion. There are currently no renewal periods included in any of the leases’ respective lease terms as they are not reasonably certain of being exercised. The Company does not have any material purchase options.

Certain of our lease agreements have rental payments that are adjusted periodically for inflation or that are based on usage. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information related to leases as of September 30, 2020 and December 31, 2019 was as follows:
Balance Sheet Caption September 30, 2020 December 31, 2019
Operating leases:
Building right-of-use assets - net Other noncurrent assets $ 100,904 $ 75,381
Equipment right-of-use assets - net Other noncurrent assets 5,431 6,993
Total right-of-use assets - net $ 106,335 $ 82,374
Operating leases:
Current lease liabilities Accrued expenses $ 15,896 $ 15,235
Noncurrent lease liabilities Other noncurrent liabilities 93,507 69,928
Total lease liabilities $ 109,403 $ 85,163

In the second quarter of 2019, the Company began to evaluate strategic alternatives for one of its businesses in the HST segment. Prior to making a final decision on the options that were presented for this business, the business was informed in the third quarter of 2019 of the loss of its largest customer. As a result, the Company accelerated its restructuring activities for this business and a decision was made to wind down the business over time. This event required an interim impairment test be performed on its long-lived assets, which resulted in an impairment charge of $ 0.6 million related to its building right-of-use asset. This charge was recorded as Restructuring expense in the Condensed Consolidated Statements of Operations. See Note 15 for further discussion.

The components of lease cost for the three and nine months ended September 30, 2020 and 2019 were as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Operating lease cost (1)
$ 7,349 $ 4,817 $ 19,663 $ 16,387
Variable lease cost 426 436 1,380 1,654
Total lease expense $ 7,775 $ 5,253 $ 21,043 $ 18,041

(1) Includes short-term leases.

Supplemental cash flow information related to leases for the nine months ended September 30, 2020 and 2019 was as follows:
Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities $ 19,198 $ 15,813
Right-of-use assets obtained in exchange for new operating lease liabilities 36,707 6,899
23
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Other supplemental information related to leases as of September 30, 2020 and December 31, 2019 was as follows:
Lease Term and Discount Rate September 30, 2020 December 31, 2019
Weighted-average remaining lease term (years):
Operating leases - building and equipment 9.65 9.61
Operating leases - vehicles 2.01 1.92
Weighted-average discount rate:
Operating leases - building and equipment 3.57 % 4.08 %
Operating leases - vehicles 2.51 % 2.99 %

The Company uses its incremental borrowing rate to determine the present value of the lease payments.

Total lease liabilities at September 30, 2020 have scheduled maturities as follows:
Maturity of Lease Liabilities
Operating Leases (1)
2020 (excluding the nine months ended September 30, 2020) $ 5,080
2021 18,593
2022 15,863
2023 13,195
2024 11,289
Thereafter 67,451
Total lease payments 131,471
Less: Imputed interest ( 22,068 )
Present value of lease liabilities $ 109,403

(1) Excludes $ 0.2 million of legally binding minimum lease payments for leases signed but not yet commenced.

Total lease liabilities at December 31, 2019 had scheduled maturities as follows:
Maturity of Lease Liabilities Operating Leases
2020 $ 18,449
2021 15,070
2022 10,647
2023 8,894
2024 7,037
Thereafter 44,284
Total lease payments 104,381
Less: Imputed interest ( 19,218 )
Present value of lease liabilities $ 85,163


15. Restructuring
During the year ended December 31, 2019 and the three and nine months ended September 30, 2020, the Company recorded accruals for restructuring costs incurred to facilitate long-term, sustainable growth through cost reduction actions, consisting of employee reductions and facility rationalization. Restructuring costs include severance benefits, exit costs and asset impairment charges and are included in Restructuring expenses in the Condensed Consolidated Statements of Operations. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services,
24
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
conditional separation costs and employer tax liabilities, while exit costs primarily consist of lease exit and contract termination costs.

In the second quarter of 2019, the Company began to evaluate strategic alternatives for one of its businesses in the HST segment. Prior to making a final decision on the options that were presented for this business, the business was informed in the third quarter of 2019 of the loss of its largest customer. As a result, the Company accelerated its restructuring activities for this business and a decision was made to wind down the business over time. This event required an interim impairment test be performed on the long-lived tangible and intangible assets of the business, which resulted in an impairment charge of $ 9.7 million, consisting of $ 6.1 million related to a customer relationships intangible asset, $ 1.0 million related to an unpatented technology intangible asset, $ 2.0 million related to property, plant and equipment and $ 0.6 million related to a building right-of-use asset. This charge was recorded as Restructuring expense in the Condensed Consolidated Statements of Operations.

Pre-tax restructuring expenses by segment for the three and nine months ended September 30, 2020 and 2019 were as follows:

Three Months Ended September 30, 2020
Severance Costs Exit Costs Asset Impairment Total
Fluid & Metering Technologies $ 500 $ — $ 85 $ 585
Health & Science Technologies 978 — — 978
Fire & Safety/Diversified Products 1,249 — — 1,249
Corporate/Other 105 — — 105
Total restructuring costs $ 2,832 $ — $ 85 $ 2,917

Three Months Ended September 30, 2019
Severance Costs Exit Costs Asset Impairment Total
Fluid & Metering Technologies $ — $ — $ — $ —
Health & Science Technologies 1,164 352 9,680 11,196
Fire & Safety/Diversified Products 104 — — 104
Corporate/Other 656 — — 656
Total restructuring costs $ 1,924 $ 352 $ 9,680 $ 11,956

Nine Months Ended September 30, 2020
Severance Costs Exit Costs Asset Impairment Total
Fluid & Metering Technologies $ 2,348 $ — $ 85 $ 2,433
Health & Science Technologies 2,162 — — 2,162
Fire & Safety/Diversified Products 1,890 — — 1,890
Corporate/Other 273 — — 273
Total restructuring costs $ 6,673 $ — $ 85 $ 6,758

25
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
Nine Months Ended September 30, 2019
Severance Costs Exit Costs Asset Impairment Total
Fluid & Metering Technologies $ 930 $ — $ — $ 930
Health & Science Technologies 1,210 636 9,680 11,526
Fire & Safety/Diversified Products 923 — — 923
Corporate/Other 703 — — 703
Total restructuring costs $ 3,766 $ 636 $ 9,680 $ 14,082

Restructuring accruals of $ 4.0 million and $ 6.1 million at September 30, 2020 and December 31, 2019, respectively, are reflected in Accrued expenses on the Condensed Consolidated Balance Sheets. Severance benefits are expected to be paid by the end of the year using cash from operations. The changes in the restructuring accrual for the nine months ended September 30, 2020 are as follows:
Restructuring
Balance at January 1, 2020 $ 6,110
Restructuring expenses 6,758
Payments, utilization and other ( 8,842 )
Balance at September 30, 2020 $ 4,026
26
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
16. Other Comprehensive Income (Loss)

The components of Other comprehensive income (loss) are as follows:
Three Months Ended September 30, 2020 Three Months Ended September 30, 2019
Pre-tax Tax Net of tax Pre-tax Tax Net of tax
Cumulative translation adjustment $ 47,343 $ — $ 47,343 $ ( 37,825 ) $ — $ ( 37,825 )
Pension and other postretirement adjustments 462 ( 171 ) 291 2,188 ( 525 ) 1,663
Reclassification adjustments for derivatives 869 ( 197 ) 672 1,566 ( 356 ) 1,210
Total other comprehensive income (loss) $ 48,674 $ ( 368 ) $ 48,306 $ ( 34,071 ) $ ( 881 ) $ ( 34,952 )
Nine Months Ended September 30, 2020 Nine Months Ended September 30, 2019
Pre-tax Tax Net of tax Pre-tax Tax Net of tax
Cumulative translation adjustment $ 40,158 $ — $ 40,158 $ ( 38,478 ) $ — $ ( 38,478 )
Pension and other postretirement adjustments 2,767 ( 811 ) 1,956 5,579 ( 1,398 ) 4,181
Reclassification adjustments for derivatives 5,153 ( 1,171 ) 3,982 4,737 ( 1,076 ) 3,661
Total other comprehensive income (loss) $ 48,078 $ ( 1,982 ) $ 46,096 $ ( 28,162 ) $ ( 2,474 ) $ ( 30,636 )

The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss) to net income during the three and nine months ended September 30, 2020 and 2019:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019 Income Statement Caption
Pension and other postretirement plans:
Amortization of net (gain) loss $ 462 $ 2,188 $ 2,767 $ 5,579 Other (income) expense - net
Total before tax 462 2,188 2,767 5,579
Provision for income taxes ( 171 ) ( 525 ) ( 811 ) ( 1,398 )
Total net of tax $ 291 $ 1,663 $ 1,956 $ 4,181
Derivatives:
Reclassification adjustments $ 869 $ 1,566 $ 5,153 $ 4,737 Interest expense, Other (income) expense -net
Total before tax 869 1,566 5,153 4,737
Provision for income taxes ( 197 ) ( 356 ) ( 1,171 ) ( 1,076 )
Total net of tax $ 672 $ 1,210 $ 3,982 $ 3,661

17. Common and Preferred Stock

On March 17, 2020, the Company’s Board of Directors approved an increase of $ 500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorizations of the Board of Directors of $ 300.0 million on December 1, 2015 and $ 400.0 million on November 6, 2014. These authorizations have no expiration date. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Facility. During the nine months ended September 30, 2020, the Company repurchased a total of 876 thousand shares at a cost of $ 110.3 million. During the nine months ended September 30, 2019, the Company repurchased a total of 389 thousand shares at a cost of $ 54.7 million. As of September 30, 2020, the amount of share repurchase authorizations remaining was $ 712.0 million.

At September 30, 2020 and December 31, 2019, the Company had 150 million shares of authorized common stock, with a par value of $ .01 per share, and five million shares of authorized preferred stock, with a par value of $ .01 per share. No preferred stock was outstanding at September 30, 2020 or December 31, 2019.

27
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
18. Share-Based Compensation

The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Board of Directors based on the recommendation from the Compensation Committee.

Stock Options

Stock options generally vest ratably over four years . Weighted average option fair values and assumptions for the periods specified are disclosed below. The fair value of each option grant was estimated on the date of the grant using the Binomial lattice option pricing model.
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Weighted average fair value of grants $ 31.60 $ 27.72 $ 34.22 $ 35.15
Dividend yield 1.18 % 1.27 % 1.15 % 1.18 %
Volatility 23.71 % 22.33 % 22.04 % 24.78 %
Risk-free interest rate
0.14 % - 0.70 %
1.75 % - 1.77 %
1.40 % - 1.66 %
2.53 % - 3.04 %
Expected life (in years) 5.81 4.65 5.80 5.87

Total compensation cost for stock options is as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Cost of goods sold $ 107 $ 74 $ 389 $ 356
Selling, general and administrative expenses 2,177 2,137 7,449 6,663
Total expense before income taxes 2,284 2,211 7,838 7,019
Income tax benefit ( 216 ) ( 288 ) ( 801 ) ( 940 )
Total expense after income taxes $ 2,068 $ 1,923 $ 7,037 $ 6,079

A summary of the Company’s stock option activity as of September 30, 2020 and changes during the nine months ended September 30, 2020 are presented in the following table:
Stock Options Shares Weighted
Average
Price 		Weighted-Average
Remaining
Contractual Term 		Aggregate
Intrinsic
Value
Outstanding at January 1, 2020 1,386,539 $ 103.58 6.95 $ 94,764,140
Granted 351,780 172.87
Exercised ( 364,063 ) 78.91
Forfeited ( 61,511 ) 142.11
Outstanding at September 30, 2020 1,312,745 $ 127.20 7.30 $ 72,470,296
Vested and expected to vest as of September 30, 2020 1,231,073 $ 125.14 7.20 $ 70,508,425
Exercisable at September 30, 2020 570,901 $ 96.07 5.75 $ 49,295,129

Restricted Stock

Restricted stock awards generally cliff vest after three years for employees and non-employee directors. Unvested restricted stock carries dividend and voting rights and the sale of the shares is restricted prior to the date of vesting. A summary of the Company’s restricted stock activity as of September 30, 2020 and changes during the nine months ended September 30, 2020 are presented as follows:
28
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
Restricted Stock Shares Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2020 130,248 $ 124.61
Granted 38,795 168.28
Vested ( 39,578 ) 95.17
Forfeited ( 16,435 ) 140.96
Unvested at September 30, 2020 113,030 $ 147.08

Dividends are paid on restricted stock awards and their fair value is equal to the market price of the Company’s stock at the date of the grant.

Total compensation cost for restricted stock awards is as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Cost of goods sold $ 69 $ ( 10 ) $ 255 $ 192
Selling, general and administrative expenses 963 1,094 2,809 3,419
Total expense before income taxes 1,032 1,084 3,064 3,611
Income tax benefit ( 217 ) ( 204 ) ( 643 ) ( 684 )
Total expense after income taxes $ 815 $ 880 $ 2,421 $ 2,927

Cash-Settled Restricted Stock

The Company also maintains a cash-settled share based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years . Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company’s stock on the last day of the quarter. A summary of the Company’s unvested cash-settled restricted stock activity as of September 30, 2020 and changes during the nine months ended September 30, 2020 are presented in the following table:
Cash-Settled Restricted Stock Shares Weighted-Average
Fair Value
Unvested at January 1, 2020 74,560 $ 172.08
Granted 20,670 173.21
Vested ( 24,810 ) 172.98
Forfeited ( 5,020 ) 182.41
Unvested at September 30, 2020 65,400 $ 182.41

Dividend equivalents are paid on certain cash-settled restricted stock awards. Total compensation cost for cash-settled restricted stock is as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Cost of goods sold $ 283 $ 118 $ 595 $ 954
Selling, general and administrative expenses 1,319 435 2,433 3,132
Total expense before income taxes 1,602 553 3,028 4,086
Income tax benefit ( 150 ) ( 67 ) ( 286 ) ( 413 )
Total expense after income taxes $ 1,452 $ 486 $ 2,742 $ 3,673
29
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)

Performance Share Units

Weighted average performance share unit fair values and assumptions for the period specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.
Nine Months Ended September 30,
2020 2019
Weighted average fair value of grants $ 224.14 $ 207.26
Dividend yield — % — %
Volatility 19.5 % 19.11 %
Risk-free interest rate 1.30 % 2.49 %
Expected life (in years) 2.94 2.83

A summary of the Company’s performance share unit activity as of September 30, 2020 and changes during the nine months ended September 30, 2020 are presented in the following table:
Performance Share Units Shares Weighted-Average
Grant Date Fair
Value
Unvested at January 1, 2020 100,575 $ 178.97
Granted 42,690 224.14
Vested — —
Forfeited ( 6,095 ) 212.47
Unvested at September 30, 2020 137,170 $ 216.26

On December 31, 2019, 54,545 performance share units vested. Based on the Company’s relative total shareholder return rank during the three year period ended December 31, 2019, the Company achieved a 250 % payout factor and issued 136,370 common shares in February 2020.

Total compensation cost for performance share units is as follows:
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Cost of goods sold $ — $ — $ — $ —
Selling, general and administrative expenses 2,572 2,359 7,225 5,904
Total expense before income taxes 2,572 2,359 7,225 5,904
Income tax benefit ( 49 ) ( 196 ) ( 157 ) ( 447 )
Total expense after income taxes $ 2,523 $ 2,163 $ 7,068 $ 5,457

The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Condensed Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees.

As of September 30, 2020, there was $ 14.9 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.4 years, $ 6.8 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 1.1 years, $ 3.9 million of total unrecognized compensation cost related to cash-settled restricted shares that is expected to be recognized over a weighted-average period of 1.0 years and $ 9.9 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.0 years.

30
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
19. Retirement Benefits

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.
Pension Benefits
Three Months Ended September 30,
2020 2019
U.S. Non-U.S. U.S. Non-U.S.
Service cost $ 34 $ 539 $ 484 $ 462
Interest cost 312 263 764 355
Expected return on plan assets ( 927 ) ( 291 ) ( 801 ) ( 258 )
Settlement loss recognized 326 — 486 —
Net amortization 643 427 487 276
Net periodic (benefit) cost $ 388 $ 938 $ 1,420 $ 835
Pension Benefits
Nine Months Ended September 30,
2020 2019
U.S. Non-U.S. U.S. Non-U.S.
Service cost $ 103 $ 1,620 $ 901 $ 1,386
Interest cost 963 789 2,292 1,081
Expected return on plan assets ( 2,804 ) ( 873 ) ( 2,403 ) ( 784 )
Settlement loss recognized 702 — 486 —
Net amortization and settlement effect 852 1,279 1,460 840
Net periodic (benefit) cost $ ( 184 ) $ 2,815 $ 2,736 $ 2,523
Other Postretirement Benefits
Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Service cost $ 154 $ 141 $ 463 $ 421
Interest cost 156 212 469 636
Net amortization ( 135 ) ( 159 ) ( 407 ) ( 476 )
Net periodic (benefit) cost $ 175 $ 194 $ 525 $ 581

The Company expects to contribute approximately $ 3.0 million to its defined benefit plans and $ 1.1 million to its other postretirement benefit plans in 2020. During the first nine months of 2020, the Company contributed a total of $ 3.0 million to fund these plans.

Effective September 30, 2019, the IDEX Corporation Retirement Plan (“Plan”), a U.S. defined benefit plan, was amended to freeze the accrual of retirement benefits for all participants. This action impacted fewer than 60 participants, as the Plan had been closed to new entrants as of December 31, 2004 and frozen as of December 31, 2005 for all but certain older, longer service participants. Subsequent to the freeze, termination of the Plan was approved in November 2019. Participants were notified in February 2020 and the Plan was terminated in May 2020. As a result of the termination, the settlement threshold was reached in early 2020 and the Company recorded a charge of $ 0.7 million to Other (income) expense - net in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2020. The settlement threshold was also reached in 2019, resulting in the Company recording a charge of $ 0.5 million in Other (income) expense - net in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2019. The settlement also
31
Table of Content

IDEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
triggered the remeasurement of net periodic benefit cost resulting in a reduction of $ 1.0 million to Other (income) expense - net in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2020 as a result of significant decreases in discount rates and strong asset performance in 2020. As of September 30, 2020, the Plan’s funded status is 110 %, with assets valued at $ 93.4 million and liabilities of $ 84.8 million.

20. Legal Proceedings

The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings arising in the ordinary course of business. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company’s business, financial condition, results of operations or cash flows.

21. Income Taxes

The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes decreased to $ 17.4 million for the three months ended September 30, 2020 compared to $ 24.0 million during the same period in 2019. The effective tax rate decreased to 14.4 % for the three months ended September 30, 2020 compared to 18.6 % during the same period in 2019 primarily due to benefits associated with the finalization of the Global Intangible Low-Tax Income (“GILTI”) regulations in the third quarter of 2020.

The provision for income taxes decreased to $ 63.8 million for the nine months ended September 30, 2020 from $ 82.2 million during the same period in 2019. The effective tax rate decreased to 18.7 % for the nine months ended September 30, 2020 compared to 20.0 % during the same period in 2019 primarily due to benefits associated with the finalization of the GILTI regulations in the third quarter of 2020.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change. However, these unrecognized tax benefits are long-term in nature and will not change within the next 12 months.


32
Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statement Under the Private Securities Litigation Reform Act

This quarterly report on Form 10-Q, including the “Overview,” “Liquidity and Capital Resources” and “Results of Operations” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated continuing effects of the coronavirus pandemic, including with respect to the Company’s sales, facility closures, supply chains and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, cash requirements, revenues, earnings, market conditions, global economies, plant and equipment capacity and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report. The risks and uncertainties include, but are not limited to, the following: the duration of the coronavirus pandemic and the continuing effects of the coronavirus on our ability to operate our business and facilities, on our customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company’s results, particularly in light of the low levels of order backlogs it typically maintains; the Company’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company’s subsequent quarterly reports, including this quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

Overview

IDEX Corporation (“IDEX,” “we,” “our,” or the “Company”) is an applied solutions company specializing in the manufacture of fluid and metering technologies, health and science technologies and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business and by the relationship of the U.S. Dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are important factors that influence the demand for IDEX’s products.

The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Within our three reportable segments, the Company maintains 13 platforms where we focus on organic growth and strategic acquisitions. Each of our 13 platforms is also a reporting unit that we annually test for goodwill impairment.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agriculture and energy industries. The Fluid & Metering Technologies segment contains the Energy platform (comprised of Corken, Liquid Controls, SAMPI, Toptech and Flow Management Devices, LLC (“Flow MD”)), the Valves platform (comprised of Alfa Valvole, Richter and Aegis), the Water platform (comprised of Pulsafeeder, OBL, Knight, ADS, Trebor and iPEK), the Pumps platform (comprised of Viking and Warren Rupp) and the Agriculture platform (comprised of Banjo).

The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-
33
Table of Contents

flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded sealing components, custom mechanical and shaft seals for a variety of end markets including food and beverage, marine, chemical, wastewater and water treatment, engineered hygienic mixers and valves for the global biopharmaceutical industry, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Health & Science Technologies segment contains the Scientific Fluidics & Optics platform (comprised of Eastern Plastics, Rheodyne, Sapphire Engineering, Upchurch Scientific, ERC, CiDRA Precision Services, thinXXS, CVI Melles Griot, Semrock, Advanced Thin Films and FLI), the Sealing Solutions platform (comprised of Precision Polymer Engineering, FTL Seals Technology, Novotema, SFC Koenig and Velcora), the Gast platform, the Micropump platform and the Material Processing Technologies platform (comprised of Quadro, Fitzpatrick, Microfluidics and Matcon).

The Fire & Safety/Diversified Products segment designs, produces and develops firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world. The Fire & Safety/Diversified Products segment is comprised of the Fire & Safety platform (comprised of Class 1, Hale, Akron Brass, Weldon, AWG Fittings, Godiva, Dinglee, Hurst Jaws of Life, Lukas and Vetter), the BAND-IT platform and the Dispensing platform.

Management’s primary measurements of segment performance are sales, operating income and operating margin. In addition, due to the highly acquisitive nature of the Company, the determination of operating income includes amortization of acquired intangible assets and as a result, management reviews depreciation and amortization as a percentage of sales. These measures are monitored by management and significant changes in operating results versus current trends in end markets and variances from forecasts are analyzed with segment management.

This report references organic sales, a non-GAAP measure, that refers to sales from continuing operations calculated according to accounting principles generally accepted in the United States of America (“U.S. GAAP”) but excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first 12 months of ownership or divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long-term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.

EBITDA, a non-GAAP measure, means earnings before interest, income taxes, depreciation and amortization. Given the acquisitive nature of the Company, which results in a higher level of amortization expense from recently acquired businesses, management uses EBITDA as an internal operating metric to provide another representation of the businesses’ performance across our three segments and for enterprise valuation purposes. Management believes that EBITDA is useful to investors as an indicator of the strength and performance of the Company and a way to evaluate and compare operating performance and value companies within our industry. Management believes that EBITDA margin is useful for the same reason as EBITDA. EBITDA is also used to calculate certain financial covenants, as discussed in Note 11 in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, “Financial Statements.”

Organic sales have been reconciled to net sales and EBITDA has been reconciled to net income in Item 2 under the heading “Non-GAAP Disclosures.” The reconciliation of segment EBITDA to net income was performed on a consolidated basis due to the fact that we do not allocate consolidated interest expense or the consolidated provision for income taxes to our segments.

Management uses Adjusted gross profit, Adjusted operating income, Adjusted net income, Adjusted EBITDA and Adjusted EPS as metrics by which to measure performance of the Company since they exclude items that are not reflective of ongoing operations, such as restructuring expenses, a fair value inventory step-up charge and a loss on early debt redemption. Management also uses free cash flow as a measure of operating performance because it provides management a measurement
34
Table of Contents

of cash generated from operations that is available for mandatory payment obligations and investment opportunities. Each of Adjusted gross profit, Adjusted operating income, Adjusted net income, Adjusted EBITDA, Adjusted EPS and free cash flow are non-GAAP measures and have been reconciled to their most directly comparable GAAP measures in this Item 2 under the heading “Non-GAAP Disclosures.”

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

Some of our key financial results for the three months ended September 30, 2020 when compared to the same period in the prior year are as follows:

• Sales of $581.1 million decreased 7%; organic sales (which excludes acquisitions and foreign currency translation) were down 12%.
• Operating income of $131.2 million decreased 7%. Adjusted for $2.9 million of restructuring expenses, adjusted operating income decreased 15% to $134.1 million.
• Net income of $103.8 million decreased 1%. Adjusted for $2.2 million of restructuring expenses, net of related tax benefit, adjusted net income decreased 9% to $106.1 million.
• EBITDA of $153.3 million was 26% of sales and covered interest expense by over 14 times. Adjusted EBITDA of $156.2 million was 27% of sales and covered interest expense by almost 15 times.
• Diluted EPS of $1.37 was flat. Adjusted EPS of $1.40 decreased 12 cents, or 8%.

Some of our key financial results for the nine months ended September 30, 2020 when compared to the same period in the prior year are as follows:

• Sales of $1,736.8 million decreased 8%; organic sales (which excludes acquisitions and foreign currency translation) were down 11%.
• Operating income of $381.7 million decreased 14%. Adjusted for a $4.1 million fair value inventory step-up charge and $6.8 million of restructuring expenses, adjusted operating income decreased 15% to $392.6 million.
• Net income of $276.7 million decreased 16%. Adjusted for the $3.2 million fair value inventory step-up charge, $5.2 million of restructuring expenses and a $6.5 million loss on early debt redemption, all net of related tax benefits, adjusted net income decreased 15% to $291.6 million.
• EBITDA of $436.4 million was 25% of sales and covered interest expense by almost 13 times. Adjusted EBITDA of $455.7 million was 26% of sales and covered interest expense by over 13 times.
• Diluted EPS of $3.64 decreased 66 cents, or 15%. Adjusted EPS of $3.84 decreased 63 cents, or 14%.

Results of Operations

The following is a discussion and analysis of our results of operations for the three and nine months ended September 30, 2020 and 2019. Segment operating income and EBITDA exclude unallocated corporate operating expenses of $14.2 million and $17.9 million for the three months ended September 30, 2020 and 2019, respectively, and $48.9 million and $55.7 million for the nine months ended September 30, 2020 and 2019, respectively.

The Company has adapted to help in the fight against COVID-19 with several of our businesses pivoting to support many products that are being used in the fight against COVID-19. We have placed safety atop our list of priorities, implementing protocols at all of our facilities, including temperature taking, social distancing, enhanced cleaning and face coverings. These measures have enabled successful business continuity, allowing our facilities to remain in operation with only temporary shutdowns at the initial onset of the COVID-19 pandemic. Although we have remained in operation throughout the pandemic, satisfying customer needs in part through our focus on the development and manufacturing of products used in the fight against COVID-19, the pandemic and the enacted containment measures have adversely affected our business and results of operations. The businesses of our customers have been harmed by the economic conditions caused by COVID-19 and as a result, our customers are purchasing less product than they have historically purchased outside of these conditions. Based on currently available information and management's current expectations, the Company anticipates that organic sales will be down approximately 3 to 5 percent in the fourth quarter of 2020 but we believe our strong balance sheet, with over $1.6 billion of liquidity and gross leverage of 1.7 times, will provide IDEX the necessary capital to navigate the COVID-19 pandemic for the foreseeable future. Additionally, IDEX implemented cost reduction actions, including employee reductions, and continues to maintain a tight cost control environment. Despite our expectations and the actions taken to reduce costs, we can provide no assurances that access to our invested cash, cash equivalents or short-term investments will not be impacted by adverse conditions in the financial markets, including, without limitation, as a result of the impact of the COVID-19 pandemic and we
35
Table of Contents

cannot predict how long the COVID-19 pandemic will continue. Moreover, COVID-19 and related measures to contain its impact have caused material disruptions in both national and global financial markets and economies. The continuing impact of COVID-19 and the enacted containment measures cannot be predicted and may continue to adversely affect, perhaps materially, our business, results of operations, financial condition and liquidity.

Consolidated Results for the Three Months Ended September 30, 2020 Compared with the Same Period in 2019
(In thousands) Three Months Ended September 30,
2020 2019
Net sales $ 581,113 $ 624,246
Operating income 131,213 141,765
Operating margin 22.6 % 22.7 %

Sales in the third quarter of 2020 were $581.1 million, which was a 7% decrease compared to the same period in 2019. This reflects a 12% decrease in organic sales, partially offset by a 1% favorable impact from foreign currency translation and a 4% increase from acquisitions (Flow MD - February 2020 and Velcora - July 2019). Sales to customers outside the U.S. represented approximately 51% of total sales in the third quarter of 2020 compared to 50% during the same period in 2019.

Gross profit of $251.5 million in the third quarter of 2020 decreased $30.5 million, or 11%, compared to the same period in 2019, and gross margin of 43.3% in the third quarter of 2020 decreased 190 basis points from 45.2% during the same period in 2019 as a result of lower volume and business mix, partially offset by price.

Selling, general and administrative expenses decreased to $117.4 million in the third quarter of 2020 from $128.3 million during the same period in 2019. The decrease is primarily due to restructuring savings, discretionary cost controls and lower variable costs. Corporate costs of $14.1 million in the third quarter of 2020 decreased from $17.2 million during the same period in 2019 primarily as a result of tightly controlling discretionary spending in the current year, restructuring savings and lower variable costs. As a percentage of sales, selling, general and administrative expenses were 20.2% for the third quarter of 2020, down 40 basis points compared to 20.6% during the same period in 2019.

The Company incurred $2.9 million of restructuring expenses in the third quarter of 2020 compared with $12.0 million during the same period in 2019. The restructuring expenses in the third quarter of 2020 primarily related to severance benefits for cost reduction actions primarily consisting of employee reductions due to lower demand as a result of the COVID-19 pandemic. The restructuring expenses in the third quarter of 2019 included severance benefits of $1.9 million and exit costs of $0.4 million as well as an asset impairment charge of $9.7 million. In the second quarter of 2019, the Company began to evaluate strategic alternatives for one of its businesses in the HST segment. Prior to making a final decision on the options that were presented for this business, the business was informed in the third quarter of 2019 of the loss of its largest customer. As a result, the Company accelerated its restructuring activities for this business and a decision was made to wind down the business over time, requiring the asset impairment charge.

Operating income of $131.2 million and operating margin of 22.6% in the third quarter of 2020 were down from $141.8 million and 22.7%, respectively, during the same period in 2019. The decreases in operating income and operating margin were driven by lower volume and business mix, partially offset by price, restructuring savings, tightly controlling discretionary spending in the current year and the asset impairment and fair value inventory step-up charges that occurred in the third quarter of 2019.

Other (income) expense - net increased to $0.7 million of income in the third quarter of 2020 compared to $1.2 million of expense during the same perio d in 2019, primarily due to a $0.7 million loss on early retirement of Velcora debt assumed at acquisition in the third quarter of 2019 that did not reoccur in 2020 , $0.5 million of higher gains on pension-related investments, $0.5 million of lower foreign currency transaction losses in 2020 compared to the same period in 2019 and $0.3 million of lower pension expense in 2020 .

Interest expense of $10.6 million in the third quarter of 2020 was lower than the $11.3 million in the same period of 2019 due to lower interest expense on the new 3.0% Senior Notes issued during the second quarter of 2020.

The provision for income taxes decreased to $17.4 million for the third quarter of 2020 compared to $24.0 million during the same period in 2019. The effective tax rate decreased to 14.4% for the third quarter of 2020 compared to 18.6% during the
36
Table of Contents

same period in 2019 primarily due to benefits associated with the finalization of the Global Intangible Low-Tax Income (“GILTI”) regulations in the third quarter of 2020.

Net income in the third quarter of 2020 of $103.8 million decreased from $105.2 million during the same period in 2019. Diluted earnings per share in the third quarter of 2020 of $1.37 was flat compared to the same period in 2019.

For the three months ended September 30, 2020, Fluid & Metering Technologies contributed 38% of sales, 40% of operating income and 40% of EBITDA; Health & Science Technologies contributed 38% of sales, 34% of operating income and 36% of EBITDA; and Fire & Safety/Diversified Products contributed 24% of sales, 26% of operating income and 24% of EBITDA. These percentages are calculated on the basis of total segment (not total Company) sales, operating income and EBITDA.

Fluid & Metering Technologies Segment
(In thousands) Three Months Ended September 30,
2020 2019
Net sales $ 220,747 $ 240,861
Operating income 58,402 77,481
Operating margin 26.5 % 32.2 %

Sales of $220.7 million decreased $20.1 million, or 8%, in the third quarter of 2020 compared to the same period in 2019. This reflects a 17% decrease in organic sales, partially offset by a 1% favorable impact from foreign currency translation and an 8% percent increase from acquisitions (Flow MD - February 2020). In the third quarter of 2020, sales decreased 9% domestically and 8% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 45% of total segment sales in the third quarters of both 2020 and 2019.

Sales within our Pumps platform decreased in the third quarter of 2020 compared to the same period in 2019 due to continued market declines in industrial and oil and gas markets, compounded by the continued impact of the COVID-19 pandemic driving reduced capital spending. Sales within our Valves platform decreased in the third quarter of 2020 compared to the same period in 2019 due to the softening global industrial landscape and lower energy prices driving decreases in capital spending. Sales within our Agriculture platform decreased in the third quarter of 2020 compared to the same period in 2019 due to timing of pre-season programs and decreased demand across both the agricultural and industrial original equipment manufacturer (“OEM”) markets. Sales within our Water platform decreased in the third quarter of 2020 compared to the same period in 2019 primarily due to project delays from the impact of COVID-19 and market softness. Sales within our Energy platform increased in the third quarter of 2020 compared to the same period in 2019 due to the acquisition of Flow MD, partially offset by declining capital spending in the oil and gas markets.

Operating income of $58.4 million and operating margin of 26.5% in the third quarter of 2020 were lower than $77.5 million and 32.2%, respectively, recorded during the same period in 2019, primarily due to lower volume and higher restructuring expenses, partially offset by price, restructuring savings and tightly controlling discretionary spending in the current year.

Health & Science Technologies Segment
(In thousands) Three Months Ended September 30,
2020 2019
Net sales $ 220,378 $ 229,610
Operating income 49,912 40,170
Operating margin 22.6 % 17.5 %

Sales of $220.4 million decreased $9.2 million, or 4%, in the third quarter of 2020 compared to the same period in 2019. This reflects a 6% decrease in organic sales, partially offset by a 1% favorable impact from foreign currency translation and a 1% increase from acquisitions (Velcora - July 2019). In the third quarter of 2020, sales decreased 5% domestically and 3% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 55% of total segment sales in both the third quarters of 2020 and 2019.

37
Table of Contents

Sales within our Micropump platform decreased in the third quarter of 2020 compared to the same period in 2019 due to lower demand from customers in the inkjet printing market. Sales within our Scientific Fluidics & Optics platform decreased in the third quarter of 2020 compared to the same period in 2019 due to the impact of the COVID-19 pandemic which limited or delayed investments in Analytical Instrumentation due to lab closures and IVD/Bio due to lower demand for non-COVID applications, partially offset by increased demand for microfluidics and optical solutions supporting COVID-19 testing applications. Sales within our Gast platform decreased in the third quarter of 2020 compared to the same period in 2019 primarily due to the non-repeat of a large customer project and a slowdown across various industrial end markets, partially offset by new initiatives in response to the COVID-19 pandemic. Sales within our Sealing Solutions platform decreased in the third quarter of 2020 compared to the same period in 2019 primarily due to disruption in the automotive and oil and gas markets, partially offset by the Velcora acquisition and the recovery in the semiconductor market. Sales within our Material Processing Technologies platform increased in the third quarter of 2020 compared to the same period in 2019 primarily due to strong volumes in the food and pharmaceutical industries.

Operating income of $49.9 million and operating margin of 22.6% in the third quarter of 2020 were higher than $40.2 million and 17.5%, respectively, recorded during the same period in 2019, primarily due to the asset impairment and fair value inventory-step up charges that occurred in the prior year period, price, restructuring savings and tightly controlling discretionary spending in the current year, partially offset by lower volume and the impact on margins from the Velcora acquisition.

Fire & Safety/Diversified Products Segment
(In thousands) Three Months Ended September 30,
2020 2019
Net sales $ 140,896 $ 154,543
Operating income 37,103 41,967
Operating margin 26.3 % 27.2 %

Sales of $140.9 million decreased $13.6 million, or 9%, in the third quarter of 2020 compared to the same period in 2019. This reflects a 10% decrease in organic sales, partially offset by a 1% favorable impact from foreign currency translation. In the third quarter of 2020, sales decreased 12% domestically and 6% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 54% of total segment sales in the third quarter of 2020 compared to 52% during the same period in 2019.

Sales within our Dispensing platform decreased in the third quarter of 2020 compared to the same period in 2019 primarily due to the non-repeat of large projects in North America. Sales within our Band-It platform decreased in the third quarter of 2020 compared to the same period in 2019 due to continued softness in the industrial and transportation markets as a result of the COVID-19 pandemic and lower capital spending in the energy markets. Sales within our Fire & Safety platform decreased in the third quarter of 2020 compared to the same period in 2019 due to timing of large projects and market softness globally for the Fire business.

Operating income of $37.1 million and operating margin of 26.3% in the third quarter of 2020 were lower than $42.0 million and 27.2%, respectively, during the same period in 2019. Operating income and operating margin decreased compared to the prior period as a result of lower volume and higher restructuring expenses, partially offset by price, restructuring savings and tightly controlling discretionary spending in the current year.

Consolidated Results for the Nine Months Ended September 30, 2020 Compared with the Same Period in 2019
(In thousands) Nine Months Ended September 30,
2020 2019
Net sales $ 1,736,824 $ 1,888,576
Operating income 381,748 444,830
Operating margin 22.0 % 23.6 %

Sales in the first nine months of 2020 were $1,736.8 million, which was an 8% decrease compared to the same period in 2019. This reflects an 11% decrease in organic sales, partially offset by a 3% increase from acquisitions (Flow MD - February 2020 and Velcora - July 2019). Sales to customers outside the U.S. represented approximately 50% of total sales in the first nine months of 2020 and 2019.
38
Table of Contents


Gross profit of $758.3 million in the first nine months of 2020 decreased $99.9 million, or 12%, compared to the same period in 2019 and gross margin of 43.7% in the first nine months of 2020 decreased 170 basis points from 45.4% during the same period in 2019. Both gross profit and gross margin decreased compared to the prior year period primarily due to lower volume and business mix.

Selling, general and administrative expenses decreased to $369.8 million in the first nine months of 2020 from $399.2 million during the same period in 2019, primarily due to restructuring savings and lower variable costs. Corporate costs decreased to $48.6 million in the first nine months of 2020 compared to $55.0 million during the same period in 2019 primarily due to tightly controlling discretionary spending in the current year, restructuring savings and lower variable costs. As a percentage of sales, selling, general and administrative expenses were 21.3% for the first nine months of 2020, up 20 basis points compared to 21.1% during the same period in 2019.

The Company incurred $6.8 million of restructuring expenses in the first nine months of 2020 compared with $14.1 million during the same period in 2019. The restructuring expenses in the first nine months of 2020 primarily related to severance benefits for cost reduction actions primarily consisting of employee reductions due to lower demand as a result of the COVID-19 pandemic. The restructuring expenses in the third quarter of 2019 included severance benefits of $3.8 million and exit costs of $0.6 million as well as an asset impairment charge of $9.7 million. In the second quarter of 2019, the Company began to evaluate strategic alternatives for one of its businesses in the HST segment. Prior to making a final decision on the options that were presented for this business, the business was informed in the third quarter of 2019 of the loss of its largest customer. As a result, the Company accelerated its restructuring activities for this business and a decision was made to wind down the business over time, requiring the asset impairment charge.

Operating income of $381.7 million and operating margin of 22.0% in the first nine months of 2020 were down from the $444.8 million and 23.6%, respectively, recorded during the same period in 2019. The decreases in operating income and operating margin are primarily due to lower volume, the dilutive impact on margins from the Velcora acquisition and the fair value inventory step-up charge, partially offset by price, lower restructuring expenses in 2020 and an overall reduction in variable costs.

Other (income) expense - net was $7.3 million of expense in the first nine months of 2020 compared to $0.7 million of expense during the same period in 2019, primarily due to an $8.4 million loss on early debt redemption, partially offset by $1.7 million of lower pension expense in 2020.

Interest expense of $34.0 million in the first nine months of 2020 was higher than the $33.3 million in the same period of 2019 due to borrowings under the Revolving Facility in 2020, partially offset by lower interest expense on the new 3.0% Senior Notes issued during the second quarter of 2020.

The provision for income taxes decreased to $63.8 million in the first nine months of 2020 compared to $82.2 million during the same period in 2019. The effective tax rate decreased to 18.7% in the first nine months of 2020 compared to 20.0% during the same period in 2019 primarily due to benefits associated with the finalization of the GILTI regulations in the third quarter of 2020.

Net income of $276.7 million in the first nine months of 2020 decreased from $328.7 million during the same period in 2019. Diluted earnings per share of $3.64 in the first nine months of 2020 decreased $0.66, or 15%, compared to the same period in 2019.

For the nine months ended September 30, 2020, Fluid & Metering Technologies contributed 38% of sales, 41% of operating income and 40% of EBITDA; Health & Science Technologies contributed 38% of sales, 35% of operating income and 37% of EBITDA; and Fire & Safety/Diversified Products contributed 24% of sales, 24% of operating income and 23% of EBITDA. These percentages are calculated on the basis of total segment (not total Company) sales, operating income and EBITDA.
39
Table of Contents


Fluid & Metering Technologies Segment
(In thousands) Nine Months Ended September 30,
2020 2019
Net sales $ 666,720 $ 729,572
Operating income 176,111 223,493
Operating margin 26.4 % 30.6 %

Sales of $666.7 million decreased $62.9 million, or 9%, in the first nine months of 2020 compared to the same period in 2019. This reflects a 15% decrease in organic sales, partially offset by a 6% increase from acquisitions (Flow MD - February 2020). In the first nine months of 2020, sales decreased 7% domestically and 11% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 42% of total segment sales in the first nine months of 2020 compared to 44% during the same period in 2019.

Sales within our Pumps platform decreased in the first nine months of 2020 compared to the same period in 2019 due to continued market declines in industrial and oil and gas markets, compounded by the continued impact of the COVID-19 pandemic, driving declines across most end markets and geographies. Sales within our Valves platform decreased in the first nine months of 2020 compared to the same period in 2019 due to the softening global industrial landscape and lower energy prices driving decreases in capital spending. Sales within our Water platform decreased in the first nine months of 2020 compared to the same period in 2019 primarily due to lower project volumes across the U.S. and Asia. Sales within our Agriculture platform decreased in the first nine months of 2020 compared to the same period in 2019 due to decreased demand across both the agricultural and industrial OEM markets. Sales within our Energy platform increased in the first nine months of 2020 compared to the same period in 2019 due to the acquisition of Flow MD, partially offset by declining capital spending in the oil and gas markets.

Operating income of $176.1 million and operating margin of 26.4% in the first nine months of 2020 were lower than the $223.5 million and 30.6%, respectively, recorded in the first nine months of 2019, primarily due to lower volume as well as higher restructuring expenses and a fair value inventory step-up charge included in the current year period, partially offset by the impact of the Flow MD acquisition, price, restructuring savings and tightly controlling discretionary spending in the current year.

Health & Science Technologies Segment
(In thousands) Nine Months Ended September 30,
2020 2019
Net sales $ 660,105 $ 687,153
Operating income 150,562 151,087
Operating margin 22.8 % 22.0 %

Sales of $660.1 million decreased $27.0 million, or 4%, in the first nine months of 2020 compared to the same period in 2019. This reflects a 7% decrease in organic sales, partially offset by a 3% increase from acquisitions (Velcora - July 2019). In the first nine months of 2020, sales decreased 7% domestically and 2% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 56% of total segment sales in the first nine months of 2020 compared to 55% during the same period in 2019.

Sales within our Gast platform decreased in the first nine months of 2020 compared to the same period in 2019 primarily due to the non-repeat of a large customer project and a slowdown across various industrial end markets, partially offset by new initiatives in response to the COVID-19 pandemic. Sales within our Micropump platform decreased in the first nine months of 2020 compared to the same period in 2019 due to weakness in core printing and industrial distribution. Sales within our Scientific Fluidics & Optics platform decreased in the first nine months of 2020 compared to the same period in 2019 due to the impact of the COVID-19 pandemic, which limited or delayed investments in Analytical Instrumentation and IVD/Bio due to lab closures and lower demand for non-COVID applications, partially offset by increased demand for microfluidics and optical solutions supporting COVID-19 testing applications. Sales within our Sealing Solutions platform increased in the first nine months of 2020 compared to the same period in 2019 primarily due to the Velcora acquisition and the recovery in the semiconductor market, partially offset by disruption in the automotive and oil and gas markets. Sales within our Material Processing Technologies platform increased in the first nine months of 2020 compared to the same period in 2019 primarily due
40
Table of Contents

to strong volumes in the food and pharmaceutical industry in response to the COVID-19 pandemic, partially offset by the non-repeat of large projects from the prior year.
Operating income of $150.6 million in the first nine months of 2020 was lower than the $151.1 million recorded during the same period in 2019 while operating margin of 22.8% in the first nine months of 2020 was higher than the 22.0% recorded during the same period in 2019. The decrease in operating income was primarily due to lower volume. The increase in operating margin was due to restructuring savings, tightly controlling discretionary spending in the current year and lower restructuring expenses in the current period, partially offset by the dilutive impact on margins from the Velcora acquisition.

Fire & Safety/Diversified Products Segment
(In thousands) Nine Months Ended September 30,
2020 2019
Net sales $ 412,296 $ 474,745
Operating income 103,977 125,909
Operating margin 25.2 % 26.5 %

Sales of $412.3 million decreased $62.4 million, or 13%, in the first nine months of 2020 compared to the same period in 2019. This reflects a 13% decrease in organic sales. In the first nine months of 2020, sales decreased 11% domestically and 16% internationally compared to the same period in 2019. Sales to customers outside the U.S. were approximately 51% of total segment sales in the first nine months of 2020 compared with 52% during the same period in 2019.

Sales within our Dispensing platform decreased in the first nine months of 2020 compared to the same period in 2019 primarily due to lower capital spending by customers as a result of the COVID-19 pandemic. Sales within our Band-It platform decreased in the first nine months of 2020 compared to the same period in 2019 due to customer shutdowns in the transportation market as a result of the COVID-19 pandemic and lower capital spending in the energy markets. Sales within our Fire & Safety platform decreased in the first nine months of 2020 compared to the same period in 2019 due to fewer large projects and market softness globally for the Fire and Rescue businesses.

Operating income of $104.0 million and operating margin of 25.2% in the first nine months of 2020 were lower than the $125.9 million and 26.5%, respectively, recorded during the same period in 2019, primarily due to lower volume and higher restructuring expenses, partially offset by price, restructuring savings and tightly controlling discretionary spending in the current year.

Liquidity and Capital Resources

Operating Activities

Cash flows from operating activities for the first nine months of 2020 increased $31.0 million, or 8%, to $407.9 million compared to the first nine months of 2019 due to favorable working capital, partially offset by lower earnings. At September 30, 2020, working capital was $1,111.1 million and the Company’s current ratio was 3.7 to 1. At September 30, 2020, the Company’s cash and cash equivalents totaled $877.8 million, of which $483.3 million was held outside of the United States. The COVID-19 pandemic has impacted and may continue to impact the Company’s operating cash flows through direct and secondary effects on the Company’s operations, customers and supply chain. Although the Company has been able to operate through the COVID-19 pandemic with only temporary shutdowns at the onset of the pandemic, any future disruptions due to operational shutdowns may impact the Company’s ability to operate as well as generate operating cash flow. Based on currently available information and management’s current expectations, the Company anticipates that it has sufficient cash on hand and sufficient access to capital to continue to fund operations for the foreseeable future. However, the continuing impact of COVID-19 and its associated containment measures cannot be predicted with certainty and may increase our borrowing costs and other costs of capital and otherwise adversely affect our business, results of operations, financial condition and liquidity, and we cannot assure that we will have access to external financing at times and on terms we consider acceptable, or at all, or that we will not experience other liquidity issues going forward.

Investing Activities

Cash flows used in investing activities for the first nine months of 2020 increased by $33.0 million to $155.6 million compared to the same period in 2019, primarily due to the acquisition of Flow MD and higher capital expenditures in 2020.

41
Table of Contents

Cash flows from operations were more than adequate to fund capital expenditures of $39.4 million and $36.8 million in the first nine months of 2020 and 2019, respectively. The COVID-19 pandemic has impacted and may continue to impact the Company’s operating cash flows, which may lead to reductions in capital expenditures. The Company believes it has sufficient operating cash flow to continue to meet current obligations and invest in planned capital expenditures. Capital expenditures are generally expenditures for machinery and equipment that support growth, improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. Management believes that the Company has ample capacity in its plants and equipment to meet demand increases for future growth in the intermediate term.

Financing Activities

Cash flows used in financing activities for the first nine months of 2020 were $20.8 million compared to $192.7 million used in financing activities during the same period in 2019, primarily as a result of proceeds from the issuance of the 3.0% Senior Notes and the repayment of debt assumed in the Velcora acquisition in the third quarter of 2019, partially offset by the early payment of the 4.5% Senior Notes as well as higher share repurchases and dividends paid in 2020.

On April 29, 2020, the Company completed a public offering of $500.0 million in aggregate principal amount of its 3.0% Senior Notes due 2030 (the “3.0% Senior Notes”). The net proceeds from the offering were approximately $494.4 million, after deducting the issuance discount of $0.9 million, the underwriting commission of $3.3 million and offering expenses of $1.4 million. The net proceeds were used to redeem and repay the $300.0 million aggregate principal amount outstanding of its 4.5% Senior Notes due December 15, 2020 and the related accrued interest and make-whole premium, with the balance used for general corporate purposes. The 3.0% Senior Notes bear interest at a rate of 3.0% per annum, which is payable semi-annually in arrears on May 1 and November 1 of each year. The 3.0% Senior Notes mature on May 1, 2030.

On April 27, 2020, the Company provided notice of its election to redeem early, on May 27, 2020, the $300.0 million aggregate principal amount outstanding of its 4.5% Senior Notes at a redemption price of $300.0 million plus a make-whole redemption premium of $6.8 million and accrued and unpaid interest of $6.1 million using proceeds from the Company’s 3.0% Senior Notes. In addition, the Company recognized the remaining $1.4 million of the pre-tax amount included in Accumulated other comprehensive income (loss) in shareholders’ equity related to the interest rate exchange agreement associated with the 4.5% Senior Notes as well as the remaining $0.1 million of deferred issuance costs and $0.1 million of the debt issuance discount associated with the 4.5% Senior Notes for a total loss on early debt redemption of $8.4 million which was recorded within Other (income) expense - net in the Condensed Consolidated Statements of Operations.

On May 31, 2019, the Company entered into a credit agreement (the “Credit Agreement”) along with certain of its subsidiaries, as borrowers (the “Borrowers”), Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, with other agents party thereto. The Credit Agreement consists of a revolving credit facility (the “Revolving Facility”), which is an $800.0 million unsecured, multi-currency bank credit facility maturing on May 31, 2024. The Credit Agreement replaced the Company’s prior five-year, $700 million credit agreement, dated as of June 23, 2015, which was due to expire in June 2020. At September 30, 2020, there was no balance outstanding under the Revolving Facility and $7.0 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility of $793.0 million.

Borrowings under the Credit Agreement bear interest, at either an alternate base rate or adjusted LIBOR plus, in each case, an applicable margin. Such applicable margin is based on the lower of the Company’s senior, unsecured, long-term debt rating or the Company’s applicable leverage ratio and can range from 0.00% to 1.275%. Based on the Company’s leverage ratio at September 30, 2020, the applicable margin was 1.00% resulting in a weighted average interest rate of 1.23% for the nine months ended September 30, 2020. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR loans, on the last day of the applicable interest period selected, or every three months from the effective date of such interest period for interest periods exceeding three months. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments pursuant to such increases may not exceed $400 million.

The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement.

On June 13, 2016, the Company completed a private placement of a $100 million aggregate principal amount of 3.20% Senior Notes due June 13, 2023 and a $100 million aggregate principal amount of 3.37% Senior Notes due June 13, 2025 (collectively, the “Notes”) pursuant to a Note Purchase Agreement dated June 13, 2016 (the “Purchase Agreement”). Each series of Notes bears interest at the stated amount per annum, which is payable semi-annually in arrears on each June 13 th and December 13 th . The Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other unsecured, unsubordinated debt. The Company may at any time prepay all, or any portion of the Notes,
42
Table of Contents

provided that such portion is greater than 5% of the aggregate principal amount of the Notes then outstanding. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole amount. In addition, the Company may repurchase the Notes by making an offer to all holders of the Notes, subject to certain conditions.

On December 9, 2011, the Company completed a public offering of $350.0 million 4.2% senior notes due December 15, 2021 (“4.2% Senior Notes”). The net proceeds from the offering of $346.2 million, after deducting a $0.9 million issuance discount, a $2.3 million underwriting commission and $0.6 million of offering expenses, were used to repay $306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2% Senior Notes bear interest at a rate of 4.2% per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.2% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all of the Company’s assets. The terms of the 4.2% Senior Notes also require the Company to make an offer to repurchase the 4.2% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the Notes: a minimum interest coverage ratio of 3.00 to 1 and a maximum leverage ratio of 3.50 to 1. In the case of the leverage ratio, there is an option to increase the ratio to 4.00 for 12 months in connection with certain acquisitions. At September 30, 2020, the Company was in compliance with both of these financial covenants, as the Company’s interest coverage ratio was 14.60 to 1 and the leverage ratio was 1.7 to 1. There are no financial covenants relating to the 3.0% Senior Notes or the 4.2% Senior Notes; however, both are subject to cross-default provisions.

On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorizations of the Board of Directors of $300.0 million on December 1, 2015 and $400.0 million on November 6, 2014. Repurchases under the program will be funded with future cash flow generation or borrowings available under the Revolving Facility. During the nine months ended September 30, 2020, the Company repurchased a total of 876 thousand shares at a cost of $110.3 million. During the nine months ended September 30, 2019, the Company repurchased a total of 389 thousand shares at a cost of $54.7 million. As of September 30, 2020, the amount of share repurchase authorization remaining is $712.0 million.

Although the COVID-19 pandemic has impacted and may continue to impact the Company’s operating cash flows, based on management’s current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company’s common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. At September 30, 2020, there was no balance outstanding under the Revolving Facility and $7.0 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility of $793.0 million. The Company believes that additional borrowings through various financing alternatives remain available if required. However, the continuing impact of COVID-19 and its associated containment measures cannot be predicted with certainty and may increase our borrowing costs and other costs of capital and otherwise adversely affect our business, results of operations, financial condition and liquidity, and we cannot assure that we will have access to external financing at times and on terms we consider acceptable, or at all, or that we will not experience other liquidity issues going forward.

Non-GAAP Disclosures

Set forth below are reconciliations of Adjusted gross profit, Adjusted operating income, Adjusted net income, Adjusted EPS, EBITDA and Adjusted EBITDA to the comparable measures of gross profit, operating income, net income and EPS, as determined in accordance with U.S. GAAP. We have reconciled Adjusted gross profit to Gross profit, Adjusted operating income to Operating income; Adjusted net income to Net income; Adjusted EPS to EPS; and consolidated EBITDA, segment EBITDA, Adjusted consolidated EBITDA and Adjusted segment EBITDA to Net income. The reconciliation of segment EBITDA to net income was performed on a consolidated basis due to the fact that we do not allocate consolidated interest expense or the consolidated provision for income taxes to our segments.

43
Table of Contents

EBITDA means earnings before interest, income taxes, depreciation and amortization. Given the acquisitive nature of the Company, which results in a higher level of amortization expense from recently acquired businesses, management uses EBITDA as an internal operating metric to provide another representation of the businesses’ performance across our three segments and for enterprise valuation purposes. Management believes that EBITDA is useful to investors as an indicator of the strength and performance of the Company and a way to evaluate and compare operating performance and value companies within our industry. Management believes that EBITDA margin is useful for the same reason as EBITDA. EBITDA is also used to calculate certain financial covenants, as discussed in Note 11 in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1, “Financial Statements.”

This report references organic sales, a non-GAAP measure, that refers to sales from continuing operations calculated according to U.S. GAAP but excludes (1) the impact of foreign currency translation and (2) sales from acquired or divested businesses during the first 12 months of ownership or divestiture. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping to identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because they can obscure underlying business trends and make comparisons of long-term performance difficult due to the varying nature, size and number of transactions from period to period and between the Company and its peers.

Management uses Adjusted gross profit, Adjusted operating income, Adjusted net income, Adjusted EPS and Adjusted EBITDA as metrics by which to measure performance of the Company since they exclude items that are not reflective of ongoing operations, such as restructuring expenses, a fair value inventory step-up charge and a loss on early debt redemption. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.

In addition to measuring our cash flow generation and usage based upon the operating, investing and financing classifications included in the Condensed Consolidated Statements of Cash Flows, we also measure free cash flow (a non-GAAP measure) which represents net cash provided by operating activities minus capital expenditures. We believe that free cash flow is an important measure of operating performance because it provides management a measurement of cash generated from operations that is available for mandatory payment obligations and investment opportunities, such as funding acquisitions, paying dividends, repaying debt and repurchasing our common stock.

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.
1. Reconciliations of the Change in Net Sales to Organic Net Sales
Three Months Ended September 30, 2020
FMT HST FSDP IDEX
Change in net sales (8) % (4) % (9) % (7) %
- Impact from acquisitions/divestitures 8 % 1 % — % 4 %
- Impact from foreign currency 1 % 1 % 1 % 1 %
Change in organic net sales (17) % (6) % (10) % (12) %
Nine Months Ended September 30, 2020
FMT HST FSDP IDEX
Change in net sales (9) % (4) % (13) % (8) %
- Impact from acquisitions/divestitures 6 % 3 % — % 3 %
- Impact from foreign currency — % — % — % — %
Change in organic net sales (15) % (7) % (13) % (11) %
44
Table of Contents

2. Reconciliations of Reported-to-Adjusted Gross Profit and Margin
(dollars in thousands) Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Gross profit $ 251,500 $ 281,978 $ 758,256 $ 858,149
+ Fair value inventory step-up charge — 3,340 4,107 3,340
Adjusted gross profit $ 251,500 $ 285,318 $ 762,363 $ 861,489
Net sales $ 581,113 $ 624,246 $ 1,736,824 $ 1,888,576
Gross profit margin 43.3 % 45.2 % 43.7 % 45.4 %
Adjusted gross profit margin 43.3 % 45.7 % 43.9 % 45.6 %

3. Reconciliations of Reported-to-Adjusted Operating Income and Margin
(dollars in thousands) Three Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
Reported operating income (loss) $ 58,402 $ 49,912 $ 37,103 $ (14,204) $ 131,213
+ Restructuring expenses 585 978 1,249 105 2,917
+ Fair value inventory step-up charge — — — — —
Adjusted operating income (loss) $ 58,987 $ 50,890 $ 38,352 $ (14,099) $ 134,130
Net sales (eliminations) $ 220,747 $ 220,378 $ 140,896 $ (908) $ 581,113
Operating margin 26.5 % 22.6 % 26.3 % n/m 22.6 %
Adjusted operating margin 26.7 % 23.1 % 27.2 % n/m 23.1 %
Three Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
Reported operating income (loss) $ 77,481 $ 40,170 $ 41,967 $ (17,853) $ 141,765
+ Restructuring expenses — 11,196 104 656 11,956
+ Fair value inventory step-up charge — 3,340 — — 3,340
Adjusted operating income (loss) $ 77,481 $ 54,706 $ 42,071 $ (17,197) $ 157,061
Net sales (eliminations) $ 240,861 $ 229,610 $ 154,543 $ (768) $ 624,246
Operating margin 32.2 % 17.5 % 27.2 % n/m 22.7 %
Adjusted operating margin 32.2 % 23.8 % 27.2 % n/m 25.2 %
45
Table of Contents

Nine Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
Reported operating income (loss) $ 176,111 $ 150,562 $ 103,977 $ (48,902) $ 381,748
+ Restructuring expenses 2,433 2,162 1,890 273 6,758
+ Fair value inventory step-up charge 4,107 — — — 4,107
Adjusted operating income (loss) $ 182,651 $ 152,724 $ 105,867 $ (48,629) $ 392,613
Net sales (eliminations) $ 666,720 $ 660,105 $ 412,296 $ (2,297) $ 1,736,824
Operating margin 26.4 % 22.8 % 25.2 % n/m 22.0 %
Adjusted operating margin 27.4 % 23.1 % 25.7 % n/m 22.6 %
Nine Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
Reported operating income (loss) $ 223,493 $ 151,087 $ 125,909 $ (55,659) $ 444,830
+ Restructuring expenses 930 11,526 923 703 14,082
+ Fair value inventory step-up charge — 3,340 — — 3,340
Adjusted operating income (loss) $ 224,423 $ 165,953 $ 126,832 $ (54,956) $ 462,252
Net sales (eliminations) $ 729,572 $ 687,153 $ 474,745 $ (2,894) $ 1,888,576
Operating margin 30.6 % 22.0 % 26.5 % n/m 23.6 %
Adjusted operating margin 30.8 % 24.2 % 26.7 % n/m 24.5 %

4. Reconciliations of Reported-to-Adjusted Net Income and EPS
(in thousands, except EPS) Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Reported net income $ 103,848 $ 105,194 $ 276,710 $ 328,671
+ Restructuring expenses 2,917 11,956 6,758 14,082
+ Tax impact on restructuring expenses (703) (2,776) (1,540) (3,336)
+ Fair value inventory step-up charge — 3,340 4,107 3,340
+ Tax impact on fair value inventory step-up charge — (735) (932) (735)
+ Loss on early debt redemption — — 8,421 —
+ Tax impact on loss on early debt redemption — — (1,912) —
Adjusted net income $ 106,062 $ 116,979 $ 291,612 $ 342,022
46
Table of Contents

Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Reported EPS $ 1.37 $ 1.37 $ 3.64 $ 4.30
+ Restructuring expenses 0.04 0.16 0.09 0.18
+ Tax impact on restructuring expenses (0.01) (0.04) (0.02) (0.04)
+ Fair value inventory step-up charge — 0.04 0.05 0.04
+ Tax impact on fair value inventory step-up charge — (0.01) (0.01) (0.01)
+ Loss on early debt redemption — — 0.11 —
+ Tax impact on loss on early debt redemption — — (0.02) —
Adjusted EPS $ 1.40 $ 1.52 $ 3.84 3.84 $ 4.47
Diluted weighted average shares 75,960 76,577 76,119 76,415
5. Reconciliations of EBITDA to Net Income
(dollars in thousands) Three Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
Operating income (loss) $ 58,402 $ 49,912 $ 37,103 $ (14,204) $ 131,213
- Other (income) expense - net (719) (32) 340 (293) (704)
+ Depreciation and amortization 7,163 10,230 3,854 104 21,351
EBITDA 66,284 60,174 40,617 (13,807) 153,268
- Interest expense 10,642
- Provision for income taxes 17,427
- Depreciation and amortization 21,351
Net income $ 103,848
Net sales (eliminations) $ 220,747 $ 220,378 $ 140,896 $ (908) $ 581,113
Operating margin 26.5 % 22.6 % 26.3 % n/m 22.6 %
EBITDA margin 30.0 % 27.3 % 28.8 % n/m 26.4 %
Three Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
Operating income (loss) $ 77,481 $ 40,170 $ 41,967 $ (17,853) $ 141,765
- Other (income) expense - net 295 1,272 (92) (256) 1,219
+ Depreciation and amortization 5,507 10,296 3,566 154 19,523
EBITDA 82,693 49,194 45,625 (17,443) 160,069
- Interest expense 11,330
- Provision for income taxes 24,022
- Depreciation and amortization 19,523
Net income $ 105,194
Net sales (eliminations) $ 240,861 $ 229,610 $ 154,543 $ (768) $ 624,246
Operating margin 32.2 % 17.5 % 27.2 % n/m 22.7 %
EBITDA margin 34.3 % 21.4 % 29.5 % n/m 25.6 %
47
Table of Contents

Nine Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
Operating income (loss) $ 176,111 $ 150,562 $ 103,977 $ (48,902) $ 381,748
- Other (income) expense - net (35) (91) 148 7,299 7,321
+ Depreciation and amortization 19,370 30,806 11,409 389 61,974
EBITDA 195,516 181,459 115,238 (55,812) 436,401
- Interest expense 33,958
- Provision for income taxes 63,759
- Depreciation and amortization 61,974
Net income $ 276,710
Net sales (eliminations) $ 666,720 $ 660,105 $ 412,296 $ (2,297) $ 1,736,824
Operating margin 26.4 % 22.8 % 25.2 % n/m 22.0 %
EBITDA margin 29.3 % 27.5 % 28.0 % n/m 25.1 %
Nine Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
Operating income (loss) $ 223,493 $ 151,087 $ 125,909 $ (55,659) $ 444,830
- Other (income) expense - net 612 1,636 273 (1,820) 701
+ Depreciation and amortization 16,653 29,438 10,745 510 57,346
EBITDA 239,534 178,889 136,381 (53,329) 501,475
- Interest expense 33,262
- Provision for income taxes 82,196
- Depreciation and amortization 57,346
Net income $ 328,671
Net sales (eliminations) $ 729,572 $ 687,153 $ 474,745 $ (2,894) $ 1,888,576
Operating margin 30.6 % 22.0 % 26.5 % n/m 23.6 %
EBITDA margin 32.8 % 26.0 % 28.7 % n/m 26.6 %
6. Reconciliations of EBITDA to Adjusted EBITDA
(dollars in thousands) Three Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
EBITDA (1)
$ 66,284 $ 60,174 $ 40,617 $ (13,807) $ 153,268
+ Restructuring expenses 585 978 1,249 105 2,917
+ Fair value inventory step-up charge — — — — —
Adjusted EBITDA $ 66,869 $ 61,152 $ 41,866 $ (13,702) $ 156,185
Adjusted EBITDA margin 30.3 % 27.7 % 29.7 % n/m 26.9 %
48
Table of Contents

Three Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
EBITDA (1)
$ 82,693 $ 49,194 $ 45,625 $ (17,443) $ 160,069
+ Restructuring expenses — 11,196 104 656 11,956
+ Fair value inventory step-up charge — 3,340 — — 3,340
Adjusted EBITDA $ 82,693 $ 63,730 $ 45,729 $ (16,787) $ 175,365
Adjusted EBITDA margin 34.3 % 27.8 % 29.6 % n/m 28.1 %
Nine Months Ended September 30, 2020
FMT HST FSDP Corporate IDEX
EBITDA (1)
$ 195,516 $ 181,459 $ 115,238 $ (55,812) $ 436,401
+ Restructuring expenses 2,433 2,162 1,890 273 6,758
+ Fair value inventory step-up charge 4,107 — — — 4,107
+ Loss on early debt redemption — — — 8,421 8,421
Adjusted EBITDA $ 202,056 $ 183,621 $ 117,128 $ (47,118) $ 455,687
Adjusted EBITDA margin 30.3 % 27.8 % 28.4 % n/m 26.2 %
Nine Months Ended September 30, 2019
FMT HST FSDP Corporate IDEX
EBITDA (1)
$ 239,534 $ 178,889 $ 136,381 $ (53,329) $ 501,475
+ Restructuring expenses 930 11,526 923 703 14,082
+ Fair value inventory step-up charge — 3,340 — — 3,340
Adjusted EBITDA $ 240,464 $ 193,755 $ 137,304 $ (52,626) $ 518,897
Adjusted EBITDA margin 33.0 % 28.2 % 28.9 % n/m 27.5 %

(1) EBITDA, a non-GAAP financial measure, is reconciled to net income, its most directly comparable GAAP financial measure, immediately above in Item 5.

7. Reconciliations of Cash Flows from Operating Activities to Free Cash Flow
(dollars in thousands) Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Cash flows from operating activities $ 153,686 $ 157,064 $ 407,899 $ 376,902
- Capital expenditures 18,353 11,031 39,438 36,773
Free cash flow $ 135,333 $ 146,033 $ 368,461 $ 340,129

Critical Accounting Policies

As discussed in the Annual Report on Form 10-K for the year ended December 31, 2019, the preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. See Part 1, Notes to the Condensed Consolidated Financial Statements, Note 1 Basis of Presentation and Significant Accounting Policies. There have been no changes to the Company’s critical accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2019.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

49
Table of Contents

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, describes the procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use financial or commodity derivative instruments for trading purposes, and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company’s outstanding long-term debt. As of September 30, 2020, the Company did not have any derivative instruments outstanding.

Foreign Currency Exchange Rates

The Company’s foreign currency exchange rate risk is limited principally to the Euro, Swiss Franc, British Pound, Canadian Dollar, Indian Rupee, Chinese Renminbi and Swedish Krona. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The effect of transaction gains and losses is reported within Other (income) expense-net in the Condensed Consolidated Statements of Operations.

Interest Rate Fluctuation

The Company does not have significant interest rate exposure due to all of the $1,044.3 million of debt outstanding as of September 30, 2020 being fixed rate debt.

Item 4. Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded, as of September 30, 2020, that the Company’s disclosure controls and procedures were effective.

There has been no change in the Company’s internal controls over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

50
Table of Contents

PART II. OTHER INFORMATION
Item 1. Legal Proceedings

The Company and its subsidiaries are party to legal proceedings as described in Note 20 in Part I, Item 1, “Legal Proceedings,” and such disclosure is incorporated by reference into this Item 1, “Legal Proceedings.” In addition, the Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.

Item 1A. Risk Factors

In light of current global economic events and conditions experienced during the nine months ended September 30, 2020, the following factors are present risks to the Company. Aside from these risk factors, there have been no changes to the Company’s risk factors described in the Annual Report on Form 10-K for the year ended December 31, 2019 that have a material impact on our condensed consolidated financial statements.

Our business, results of operations and financial condition have been and may continue to be materially adversely impacted by the recent coronavirus (COVID-19) pandemic.

The novel coronavirus (COVID-19) pandemic is a rapidly-changing situation that has negatively impacted and could continue to negatively impact the global economy. Our operating results are subject to fluctuations based on general economic conditions and have been adversely affected by the negative general economic conditions. The extent to which COVID-19 continues to impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak and business closures or business disruptions for our Company, our suppliers and our customers.
The deterioration in economic conditions materially reduced, and could continue to reduce, the Company’s sales and profitability. The financial distress our customers have experienced due to the deterioration in economic conditions has resulted in and could continue to result in reduced sales and decreased collectability of accounts receivable which has and could continue to negatively impact our results of operations. Based on currently available information and management’s current expectations, we believe the Company’s organic sales will be down approximately 3 to 5 percent in the fourth quarter of 2020. Any changes in or resurgence of the COVID-19 outbreak could also have a material impact on our ability to get the raw materials, parts and components we need to manufacture our products as our suppliers face disruptions in their businesses, closures or bankruptcy as a result of the COVID-19 outbreak. We depend greatly on our suppliers for items that are essential to the manufacturing of our products. Although we have not experienced material supply chain disruptions to date, if our suppliers fail to meet our manufacturing needs in the future, it would delay our production and our product shipments to customers and negatively affect our operations.
U.S and international government responses to the COVID-19 outbreak have included “shelter in place”, “stay at home” and similar types of orders. These orders exempt certain individuals needed to maintain continuity of operations of critical infrastructure sectors as determined by the U.S. federal and international governmental bodies. Although the Company’s operations are currently considered essential and exempt (and in some regions government lockdown mandates have been lifted), if any of the applicable exemptions are curtailed or revoked in the future, including in response to any COVID-19 resurgence, that would adversely impact our business, operating results and financial condition. Furthermore, to the extent these exemptions do not extend to our key suppliers and customers, this would also adversely impact our business, operating results and financial condition. We have also implemented work-from-home policies for certain “non-essential” employees. Although these work-from-home policies have not negatively impacted our business in any material respect to date, the COVID-19
51
Table of Contents

outbreak is dynamic and any future resurgences could negatively impact productivity, disrupt conduct of our business in the ordinary course and delay our production timelines.
Due to the large remote workforce populations, we may also face informational technology infrastructure and connectivity issues from the vendors that we rely on for certain information technologies to administer, store and support the Company’s multiple business activities. IDEX is heavily dependent on the availability and support of our technology landscape, several of which are provided by external third party service providers (e.g., Microsoft, AT&T and Verizon). Although we have not suffered any disruptions to date, any future disruptions in their operations could also negatively impact our business, operating results and financial condition.
To the extent the COVID-19 outbreak continues to adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in the risk factors included in the Annual Report on Form 10-K for the year ended December 31, 2019, such as those relating to our international operations, our ability to develop new products, our ability to execute on our growth strategy of acquisitions, our dependency on raw materials, parts and components, the effects on movements in foreign currency exchange rates on our Company, the effects on our Company that result from declines in commodity prices and our reliance on labor availability to operate and grow our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information about the Company’s purchases of its common stock during the quarter ended September 30, 2020:
Period Total Number of
Shares Purchased 		Average Price
Paid per Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans
or Programs (1)
Approximate Dollar
Value that May Yet
be Purchased
Under the Plans
or Programs (1)
July 1, 2020 to July 31, 2020 — $ — — $ 712,001,005
August 1, 2020 to August 31, 2020 — — — 712,001,005
September 1, 2020 to September 30, 2020 — — — 712,001,005
Total — $ — — $ 712,001,005
(1) On March 17, 2020, the Company’s Board of Directors approved an increase of $500.0 million in the authorized level of repurchases of common stock. This approval is in addition to the prior repurchase authorizations of the Board of Directors of $300.0 million on December 1, 2015 and $400.0 million on November 6, 2014. These authorizations have no expiration date.
52
Table of Contents

Item 6. Exhibits.

Exhibit
Number 		Description
*31.1
*31.2
*32.1
*32.2
*101 The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in Inline eXtensible Business Reporting Language (iXBRL) includes: (i) the Cover Page, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Operations, (iv) the Condensed Consolidated Statements of Comprehensive Income, (v) the Condensed Consolidated Statements of Shareholders’ Equity, (vi) the Condensed Consolidated Statements of Cash Flows, and (vii) Notes to the Condensed Consolidated Financial Statements.
*104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith

53
Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IDEX Corporation
By: /s/ WILLIAM K. GROGAN
William K. Grogan
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
By: /s/ MICHAEL J. YATES
Michael J. Yates
Vice President and Chief Accounting Officer
(Principal Accounting Officer)
Date: October 28, 2020
54
TABLE OF CONTENTS